CN102702052B - Novel diamine-containing farnesyl thiosalicylic acid derivative and preparation method and medicinal application thereof - Google Patents
Novel diamine-containing farnesyl thiosalicylic acid derivative and preparation method and medicinal application thereof Download PDFInfo
- Publication number
- CN102702052B CN102702052B CN2012102016946A CN201210201694A CN102702052B CN 102702052 B CN102702052 B CN 102702052B CN 2012102016946 A CN2012102016946 A CN 2012102016946A CN 201210201694 A CN201210201694 A CN 201210201694A CN 102702052 B CN102702052 B CN 102702052B
- Authority
- CN
- China
- Prior art keywords
- compound
- perhaps
- iii
- preparation
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 200
- 150000004985 diamines Chemical class 0.000 title claims abstract description 17
- WUILNKCFCLNXOK-CFBAGHHKSA-N salirasib Chemical class CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC1=CC=CC=C1C(O)=O WUILNKCFCLNXOK-CFBAGHHKSA-N 0.000 title claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 13
- -1 farnesyl thiosalicylic acid acyl chlorides Chemical class 0.000 claims description 287
- 150000001875 compounds Chemical class 0.000 claims description 109
- 238000006243 chemical reaction Methods 0.000 claims description 78
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 54
- 230000000694 effects Effects 0.000 claims description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 33
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 19
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 13
- 101150065749 Churc1 gene Proteins 0.000 claims description 13
- 102100038239 Protein Churchill Human genes 0.000 claims description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- 229910021529 ammonia Inorganic materials 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 10
- 235000015320 potassium carbonate Nutrition 0.000 claims description 10
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical group C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 8
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 7
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 6
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 6
- 150000001263 acyl chlorides Chemical class 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- PQLFROTZSIMBKR-UHFFFAOYSA-N ethenyl carbonochloridate Chemical compound ClC(=O)OC=C PQLFROTZSIMBKR-UHFFFAOYSA-N 0.000 claims description 6
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 6
- 150000004702 methyl esters Chemical class 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical group ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 229940125898 compound 5 Drugs 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 2
- 229940125782 compound 2 Drugs 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 201000000498 stomach carcinoma Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 4
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 83
- 238000005160 1H NMR spectroscopy Methods 0.000 description 56
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 56
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 50
- 229960001138 acetylsalicylic acid Drugs 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 42
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical class NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 38
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 37
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 29
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 21
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 21
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 21
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 21
- GGNMTJKRHHLJHH-UHFFFAOYSA-N Trimethylaethergallussaeure-amid Natural products COC1=CC(C(N)=O)=CC(OC)=C1OC GGNMTJKRHHLJHH-UHFFFAOYSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000003921 oil Substances 0.000 description 16
- 230000006907 apoptotic process Effects 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 12
- 238000003756 stirring Methods 0.000 description 10
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 9
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 9
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 7
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 6
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 6
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 6
- LDSQQXKSEFZAPE-UHFFFAOYSA-N 2-piperidin-4-ylethanol Chemical compound OCCC1CCNCC1 LDSQQXKSEFZAPE-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 5
- 102000003952 Caspase 3 Human genes 0.000 description 5
- 108090000397 Caspase 3 Proteins 0.000 description 5
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 108700000707 bcl-2-Associated X Proteins 0.000 description 5
- 102000055102 bcl-2-Associated X Human genes 0.000 description 5
- 125000006278 bromobenzyl group Chemical group 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000010025 steaming Methods 0.000 description 5
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000000452 restraining effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- PXAVRWJOPPIPBN-UHFFFAOYSA-N 2-(1-ethylpiperidin-4-yl)ethanol Chemical compound CCN1CCC(CCO)CC1 PXAVRWJOPPIPBN-UHFFFAOYSA-N 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- CIRBPLONNSURCQ-UHFFFAOYSA-N 1-ethyl-4-propylpiperidine Chemical compound CCCC1CCN(CC)CC1 CIRBPLONNSURCQ-UHFFFAOYSA-N 0.000 description 2
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 2
- IWPZKOJSYQZABD-UHFFFAOYSA-N 3,4,5-trimethoxybenzoic acid Natural products COC1=CC(OC)=CC(C(O)=O)=C1 IWPZKOJSYQZABD-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- SJSOFNCYXJUNBT-UHFFFAOYSA-N Eudesmic acid Natural products COC1=CC(C(O)=O)=CC(OC)=C1OC SJSOFNCYXJUNBT-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000005775 apoptotic pathway Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229950008669 salirasib Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 1
- FOLCUFKJHSQMEL-BIXPGCQOSA-N (4-butylcyclohexyl) N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamate Chemical compound CCCCC1CCC(CC1)OC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]2CCNC2=O)C=O FOLCUFKJHSQMEL-BIXPGCQOSA-N 0.000 description 1
- PNHBRYIAJCYNDA-VQCQRNETSA-N (4r)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(CC)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 PNHBRYIAJCYNDA-VQCQRNETSA-N 0.000 description 1
- AXQACEQYCPKDMV-RZAWKFBISA-N (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-n-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3C(O)=C(C[C@]2(O)[C@]34CC1)C(=O)NC(C)(C)C=1ON=C(N=1)C=1C=CC=CC=1)CC1CC1 AXQACEQYCPKDMV-RZAWKFBISA-N 0.000 description 1
- QOLHWXNSCZGWHK-BWBORTOCSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecylcarbamoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)NCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QOLHWXNSCZGWHK-BWBORTOCSA-N 0.000 description 1
- UXKLQDCALAWFIU-VKNDCNMPSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-tetradecoxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCCCC)C1=CC=CC=C1 UXKLQDCALAWFIU-VKNDCNMPSA-N 0.000 description 1
- VGNCBRNRHXEODV-XXVHXNRLSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-dodecoxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCC)C1=CC=CC=C1 VGNCBRNRHXEODV-XXVHXNRLSA-N 0.000 description 1
- JENUMEXEVAAAJX-SNVBAGLBSA-N 2-(3,5-dimethyl-1,2,4-triazol-1-yl)-1-[(2r)-2-methyl-4-[2-(trifluoromethyl)-4-[2-(trifluoromethyl)pyrimidin-5-yl]-1,3-thiazol-5-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1C)N(C2=C(N=C(S2)C(F)(F)F)C=2C=NC(=NC=2)C(F)(F)F)CCN1C(=O)CN1N=C(C)N=C1C JENUMEXEVAAAJX-SNVBAGLBSA-N 0.000 description 1
- IOOWNWLVCOUUEX-WPRPVWTQSA-N 2-[(3r,6s)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid Chemical compound OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC1=CC=CS1 IOOWNWLVCOUUEX-WPRPVWTQSA-N 0.000 description 1
- PPSMYAUEJRADFE-HXUWFJFHSA-N 2-[(5r)-4-[2-[3-(6-methylpyridin-3-yl)oxyphenyl]acetyl]-8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-5-yl]acetic acid Chemical compound C1=NC(C)=CC=C1OC1=CC=CC(CC(=O)N2[C@@H](C3=CC=C(N=C3NCC2)C(F)(F)F)CC(O)=O)=C1 PPSMYAUEJRADFE-HXUWFJFHSA-N 0.000 description 1
- JGMXNNSYEFOBHQ-OWOJBTEDSA-N 2-[(e)-4-morpholin-4-ylbut-2-enyl]-1,1-dioxothieno[3,2-e]thiazine-6-sulfonamide Chemical compound O=S1(=O)C=2SC(S(=O)(=O)N)=CC=2C=CN1C\C=C\CN1CCOCC1 JGMXNNSYEFOBHQ-OWOJBTEDSA-N 0.000 description 1
- ZRCAHGVDEKPRSE-UHFFFAOYSA-N 3-(1h-pyrrol-2-yl)propan-1-amine Chemical compound NCCCC1=CC=CN1 ZRCAHGVDEKPRSE-UHFFFAOYSA-N 0.000 description 1
- RGUABPVONIGVAT-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)propan-1-amine Chemical compound CN1CCN(CCCN)CC1 RGUABPVONIGVAT-UHFFFAOYSA-N 0.000 description 1
- DNTVJEMGHBIUMW-IBGZPJMESA-N 3-[[4-[(1s)-1-[3-(3,5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)pyrazol-1-yl]ethyl]benzoyl]amino]propanoic acid Chemical compound C1([C@H](C)N2N=C(C=C2C2=CC3=CC=C(C=C3C=C2)OC)C=2C=C(Cl)C=C(Cl)C=2)=CC=C(C(=O)NCCC(O)=O)C=C1 DNTVJEMGHBIUMW-IBGZPJMESA-N 0.000 description 1
- GOAKYBVMJUXOFY-LBPRGKRZSA-N 3-amino-4-[(3S)-3-(2-ethoxyethoxymethyl)piperidin-1-yl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound CCOCCOC[C@@H](CCC1)CN1C1=C(C(N)=C(C(N)=O)S2)C2=NC=C1 GOAKYBVMJUXOFY-LBPRGKRZSA-N 0.000 description 1
- OVDGUTHABMXVMI-UHFFFAOYSA-N 3-nitro-4-(propylamino)benzoic acid Chemical compound CCCNC1=CC=C(C(O)=O)C=C1[N+]([O-])=O OVDGUTHABMXVMI-UHFFFAOYSA-N 0.000 description 1
- WNANVRPOLIBTIE-UHFFFAOYSA-N 4-(1h-pyrrol-2-yl)butan-1-amine Chemical compound NCCCCC1=CC=CN1 WNANVRPOLIBTIE-UHFFFAOYSA-N 0.000 description 1
- DJSWNINDPRRCLC-GOSISDBHSA-N 7-methyl-n-[(2r)-1-phenoxypropan-2-yl]-3-(4-propan-2-ylphenyl)pyrazolo[1,5-a]pyrimidine-6-carboxamide Chemical compound C([C@@H](C)NC(=O)C1=C(N2N=CC(=C2N=C1)C=1C=CC(=CC=1)C(C)C)C)OC1=CC=CC=C1 DJSWNINDPRRCLC-GOSISDBHSA-N 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- QUMCIHKVKQYNPA-RUZDIDTESA-N C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC Chemical compound C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC QUMCIHKVKQYNPA-RUZDIDTESA-N 0.000 description 1
- 125000006519 CCH3 Chemical group 0.000 description 1
- 229940126559 Compound 4e Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000007563 Galectins Human genes 0.000 description 1
- 108010046569 Galectins Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940121849 Mitotic inhibitor Drugs 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- TZCCKCLHNUSAMQ-DUGSHLAESA-N NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N Chemical compound NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N TZCCKCLHNUSAMQ-DUGSHLAESA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229940078123 Ras inhibitor Drugs 0.000 description 1
- 229940125907 SJ995973 Drugs 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 208000024055 brain glioblastoma Diseases 0.000 description 1
- 201000011609 brain glioblastoma multiforme Diseases 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125872 compound 4d Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- USLKCMBGQFYUFI-UHFFFAOYSA-N dichloromethane;tribromoborane Chemical compound ClCCl.BrB(Br)Br USLKCMBGQFYUFI-UHFFFAOYSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- GCOWZPRIMFGIDQ-UHFFFAOYSA-N n',n'-dimethylbutane-1,4-diamine Chemical compound CN(C)CCCCN GCOWZPRIMFGIDQ-UHFFFAOYSA-N 0.000 description 1
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 1
- IETFBKOGVBSBJQ-UHFFFAOYSA-N n-butylpiperidin-4-amine Chemical compound CCCCNC1CCNCC1 IETFBKOGVBSBJQ-UHFFFAOYSA-N 0.000 description 1
- GADIREFQKKSFKX-UHFFFAOYSA-N n-propylmorpholin-4-amine Chemical compound CCCNN1CCOCC1 GADIREFQKKSFKX-UHFFFAOYSA-N 0.000 description 1
- CBIBYLPZGDCTJB-UHFFFAOYSA-N n-propylpiperidin-3-amine Chemical compound CCCNC1CCCNC1 CBIBYLPZGDCTJB-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- PFGVNLZDWRZPJW-OPAMFIHVSA-N otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- XBXHCBLBYQEYTI-UHFFFAOYSA-N piperidin-4-ylmethanol Chemical compound OCC1CCNCC1 XBXHCBLBYQEYTI-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940103494 thiosalicylic acid Drugs 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a novel diamine-containing farnesyl thiosalicylic acid derivative and pharmaceutically acceptable salt thereof, a preparation method for the derivative and the salt, a medicinal composition containing the derivative, and medicinal application of the derivative, the salt and the composition, particularly application to preparation of anti-tumor medicines and neuroprotection medicines.
Description
Technical field
The present invention relates to biomedicine field; be specifically related to novel farnesyl thio-salicylic acid derivative and pharmacy acceptable salt thereof that a class contains Diamines; their preparation method; the medicinal compositions that contains these derivatives and their medicinal use, the particularly application in preparing antitumor drug and nerve protection medicine.
Background technology
Alltrans farnesyl thiosalicylic acid (is called for short: FTA, trade(brand)name: Salirasib) be first Ras protein inhibitor based on farnesyl, can competitive replace F-Ras and the F-Ras mutain is combined with Galectins, inhibition causes downstream signal path (comprising Raf and P13K signal path) and mTOR (tumorigenic stimulator by Ras, it can rely on or open independently the P13K signal path), thereby the promotion apoptosis of tumor cells, the growth of inhibition tumor cell.Research shows, the IC of FTA to breast cancer cell MCF-7 and MBA-MD-231
50in 75 μ M left and right; To brain glioblastoma cell U87 (IC
50=50 μ M), carcinoma of the pancreas Panc-1 (IC
50=35 μ M), lung cell A549 (IC
50=40 μ M), H23 (IC50=75 μ M), HTB58 (IC
50=50 μ M) restraining effect is all arranged.FTA(oral administration, dosage 40mg/kg) to the inhibitory rate to 54.6% of nude mice Panc-1 transplanted tumor.Pharmacokinetic shows, under above-mentioned dosage, the transformation period of FTA in the rat body is 141.6min(Zundelevich A, Elad-Sfadia G, Haklai R, et al.Mol Cancer Ther, 2007,6 (6): 1765-1773; Goldberg L, Haklai R, Bauer V. et al.J Med Chem, 2009,52 (1): 197-205).Because FTA has anti-tumor activity and less toxic side effect preferably, now entered clinical II phase research, treatment lung cancer and carcinoma of the pancreas (Riely GJ, Johnson ML, Medina C, et al.J Thorac Oncol, 2011,6 (8): 1435-1437; Bustinza-Linares E, Kurzrock R, Tsimberidou AM, et al.Future Oncol, 2010,6 (6): 885-891).Yet, though FTA is in the clinical study of II phase, because it can't stop and reversion of malignant tumor development process forcefully, and clinical therapeutic efficacy is not high, using dosage is large, usually needs clinically to have the antitumour drug combination therapy of cytotoxicity with other.According to another bibliographical information, Ras inhibitor FTA also has neuroprotective (Marciano D, Shohami E, Kloog Y, et al.J Neurotrauma, 2007,24 (8): 1378-86 of long-acting closed injury of brain; Shohami E, Yatsiv I, Alexandrovich A, Haklai R, et al.J Cereb Blood Flow Metab, 2003,23 (6): 728-38).
Farnesyl thiosalicylic acid (FTA, Salirasib)
For this reason; we are according to life science and information science latest Progress; Advanced Idea and the means of the design of application new drug are modified, are transformed the FTA structure; introduce other pharmacophoric group; for obtaining than FTA anti-tumor activity or the stronger compound of brain injury neuroprotective; the invention discloses the novel FTA derivative of Diamines and pharmacy acceptable salt thereof that a class has pharmaceutical use, have not yet to see any report to this compounds.
Summary of the invention
The present invention discloses new diamine class FTA derivative and pharmacy acceptable salt, its preparation method and the medicinal use thereof that a class has anti-tumor activity first.Compound disclosed by the invention is new diamine class FTA derivative and the pharmacy acceptable salt thereof shown in general formula I, II and III:
In formula I: n=1 ~ 9;
R
1represent H, CH
3(CH
3) CH, CH
3(CH
3) CHCH
2, Cyclohexyl, Cyclopentyl or X (CH
2)
m, wherein
M=0 ~ 9, X=H, OH, NH2, Cl, F, CN, COOH, Ph or PhCH
2;
R
2represent H, CH
3(CH
3) CH, CH
3(CH
3) CHCH
2, Cyclohexyl, Cyclopentyl or Y (CH
2)
p, wherein,
P=0 ~ 9, Y=H, OH, NH2, Cl, F, CN, COOH, Ph or PhCH
2;
In the general formula II: m=0 ~ 9; X=CH, N; N=0 ~ 3; O=0 ~ 3;
R represents CH
3(CH
3) CH, CH
3(CH
3) CHCH
2, Cyclohexyl, Cyclopentyl or Y (CH
2)
p, wherein, p=0 ~ 9, Y=H, OH, NH
2, Cl, F, CN, COOH, Ph or PhCH
2.
In the general formula III: n=1 ~ 9;
R representative-X (CH
2)
ny, wherein X=O, NH or CH
2, n=0 ~ 8, Y=H, OH, NH2, CN, COOH, COOMe, Cl, F, OCH
3, OCH
2cH
3, NHCH
3or NHCH
2cH
3;
Perhaps, R represents Ph, 2-OHPh, 2-SHPh, 2-S-farnesyl-Ph, 2-OAcPh, 2-SAcPh, 3-OHPh, 4-OHPh, 3,4-OHPh, 3,5-OHPh, 3,4,5-OHPh, 3-OMePh, 4-OMePh, 3,4-OMePh, 3,5-OMePh, 3,4,5-OMePh,
perhaps
r wherein
3=H, OH or OCH
3, R
4=H, OH or OCH
3;
Perhaps, RCO represents L-or D-type L-Ala, L-or D-type phenylalanine, L-or D-type methionine(Met), L-or D-type leucine, L-or D-type Isoleucine, L-or D-type Methionin, L-or D-type proline(Pro), L-or D-type glutamine or L-or D-type l-asparagine.
Specifically, the Diamines FTA derivative shown in general formula I is preferably from following compounds:
N-(2-aminoethyl) farnesyl thiosalicylic acid acid amides (compound number: I
1, lower same)
N-(3-aminopropyl) farnesyl thiosalicylic acid acid amides (I
2)
N-(4-ammonia butyl) farnesyl thiosalicylic acid acid amides (I
3)
N-(5-ammonia amyl group) farnesyl thiosalicylic acid acid amides (I
4)
N-(6-ammonia hexyl) farnesyl thiosalicylic acid acid amides (I
5)
N-(3-dimethylamino-propyl) farnesyl thiosalicylic acid acid amides (I
6)
N-(3-diethylin propyl group) farnesyl thiosalicylic acid acid amides (I
7)
N-(3-dipropyl aminopropyl) farnesyl thiosalicylic acid acid amides (I
8)
N-(4-dimethylamino butyl) farnesyl thiosalicylic acid acid amides (I
9)
N-(4-diethylin butyl) farnesyl thiosalicylic acid acid amides (I
10)
N-(3-piperidyl propyl group) farnesyl thiosalicylic acid acid amides (I
11)
N-(3-pyrryl propyl group) farnesyl thiosalicylic acid acid amides (I
12)
N-(3-(4-methylpiperazine-1-yl) propyl group) farnesyl thiosalicylic acid acid amides (I
13)
N-(4-piperidyl butyl) farnesyl thiosalicylic acid acid amides (I
14)
N-(4-pyrryl butyl) farnesyl thiosalicylic acid acid amides (I
15)
N-(morpholinyl propyl group) farnesyl thiosalicylic acid acid amides (I
16)
N-(3-(N, N-dihydroxy ethyl)-aminopropyl) farnesyl thiosalicylic acid acid amides (I
17)
N-(2-(N-hydroxyethyl)-amino-ethyl) farnesyl thiosalicylic acid acid amides (I
18)
Diamines FTA derivative shown in the general formula II is preferably from following compounds:
N-(2-(1-benzyl piepridine-4-yl) ethyl) farnesyl thiosalicylic acid acid amides (II
1)
N-(2-(1-benzyl piepridine-4-yl) methyl) farnesyl thiosalicylic acid acid amides (II
2)
N-(2-(1-ethyl piperidine-4-yl) ethyl) farnesyl thiosalicylic acid acid amides (II
3)
N-(2-(1-benzyl diethylenediamine-4-yl) ethyl) farnesyl thiosalicylic acid acid amides (II
4)
N-(2-(1-ethyl piperazidine-4-yl) ethyl) farnesyl thiosalicylic acid acid amides (II
5)
Diamines FTA derivative shown in the general formula III is preferably from following compounds:
N-(2-(Aspirin amide group) ethyl) farnesyl thiosalicylic acid acid amides (III
1)
N-(3-(Aspirin amide group) propyl group) farnesyl thiosalicylic acid acid amides (III
2)
N-(4-(Aspirin amide group) butyl) farnesyl thiosalicylic acid acid amides (III
3)
N-(5-(Aspirin amide group) amyl group) farnesyl thiosalicylic acid acid amides (III
4)
N-(6-(Aspirin amide group) hexyl) farnesyl thiosalicylic acid acid amides (III
5)
N-(2-(3-(3-methoxyl group-4-acetoxyl group phenyl)-2-allyl acid amide group) ethyl) farnesyl thiosalicylic acid acid amides (III
6)
N-(3-(3-(3-methoxyl group-4-acetoxyl group phenyl)-2-allyl acid amide group) propyl group) farnesyl thiosalicylic acid acid amides (III
7)
N-(4-(3-(3-methoxyl group-4-acetoxyl group phenyl)-2-allyl acid amide group) butyl) farnesyl thiosalicylic acid acid amides (III
8)
N-(5-(3-(3-methoxyl group-4-acetoxyl group phenyl)-2-allyl acid amide group) amyl group) farnesyl thiosalicylic acid acid amides (III
9)
N-(6-(3-(3-methoxyl group-4-acetoxyl group phenyl)-2-allyl acid amide group) hexyl) farnesyl thiosalicylic acid acid amides (III
10)
N-(2-(3,4,5-trimethoxybenzoic acid amide group) ethyl) farnesyl thiosalicylic acid acid amides (III
11)
N-(3-(3,4,5-trimethoxybenzoic acid amide group) propyl group) farnesyl thiosalicylic acid acid amides (III
12)
N-(4-(3,4,5-trimethoxybenzoic acid amide group) butyl) farnesyl thiosalicylic acid acid amides (III
13)
N-(5-(3,4,5-trimethoxybenzoic acid amide group) amyl group) farnesyl thiosalicylic acid acid amides (III
14)
N-(6-(3,4,5-trimethoxybenzoic acid amide group) hexyl) farnesyl thiosalicylic acid acid amides (III
15)
N-(2-(2 hydroxybenzoic acid amide group) ethyl) farnesyl thiosalicylic acid acid amides (III
16)
N-(3-(2 hydroxybenzoic acid amide group) propyl group) farnesyl thiosalicylic acid acid amides (III
17)
N-(4-(2 hydroxybenzoic acid amide group) butyl) farnesyl thiosalicylic acid acid amides (III
18)
N-(5-(2 hydroxybenzoic acid amide group) amyl group) farnesyl thiosalicylic acid acid amides (III
19)
N-(6-(2 hydroxybenzoic acid amide group) hexyl) farnesyl thiosalicylic acid acid amides (III
20)
N-(2-(3-(3-methoxyl group-4-hydroxy phenyl)-2-allyl acid amide group) ethyl) farnesyl thiosalicylic acid acid amides (III
21)
N-(3-(3-(3-methoxyl group-4-hydroxy phenyl)-2-allyl acid amide group) propyl group) farnesyl thiosalicylic acid acid amides (III
22)
N-(4-(3-(3-methoxyl group-4-hydroxy phenyl)-2-allyl acid amide group) butyl) farnesyl thiosalicylic acid acid amides (III
23)
N-(5-(3-(3-methoxyl group-4-hydroxy phenyl)-2-allyl acid amide group) amyl group) farnesyl thiosalicylic acid acid amides (III
24)
N-(6-(3-(3-methoxyl group-4-hydroxy phenyl)-2-allyl acid amide group) hexyl) farnesyl thiosalicylic acid acid amides (III
25)
N-(2-(Gallic Acid amide group) ethyl) farnesyl thiosalicylic acid acid amides (III
26)
N-(3-(Gallic Acid amide group) propyl group) farnesyl thiosalicylic acid acid amides (III
27)
N-(4-(Gallic Acid amide group) butyl) farnesyl thiosalicylic acid acid amides (III
28)
N-(5-(Gallic Acid amide group) amyl group) farnesyl thiosalicylic acid acid amides (III
29)
N-(6-(Gallic Acid amide group) hexyl) farnesyl thiosalicylic acid acid amides (III
30)
N-(3-farnesyl thiosalicylic acid amidopropyl) farnesyl thiosalicylic acid acid amides (III
31)
N-(4-farnesyl thiosalicylic acid amide group butyl) farnesyl thiosalicylic acid acid amides (III
32)
N-(5-farnesyl thiosalicylic acid amide group amyl group) farnesyl thiosalicylic acid acid amides (III
33)
The structure of said structure formula I preferred compound code name and correspondence thereof is as shown in table 1
Table 1 general formula I preferred compound code name and corresponding structure thereof
The structure of said structure general formula II preferred compound code name and correspondence thereof is as shown in table 2
Table 2 general formula II preferred compound code name and corresponding structure thereof
The structure of said structure general formula III preferred compound code name and correspondence thereof is as shown in table 3
Table 3 general formula III preferred compound code name and corresponding structure thereof
Another object of the present invention is to provide the preparation method of formula I of the present invention, II and the described compound of III.
The preparation of the derivative of FTA shown in formula I, its synthetic route is as follows:
Step comprises:
By FTA, under the effect of sulfur oxychloride or oxalyl chloride, preparation FTA acyl chlorides, by FTA acyl chlorides and NH
2(CH
2)
ncH
2nR
1r
2in the dichloromethane solution of triethylamine or salt of wormwood or sodium carbonate, reaction obtains compound of Formula I;
Perhaps, FTA and NH
2(CH
2)
ncH
2nR
1r
2under condensing agent and DMAP (DMAP) effect, condensation makes compound of Formula I.
Wherein, n=1 ~ 9;
R
1represent H, CH
3(CH
3) CH, CH
3(CH
3) CHCH
2, Cyclohexyl, Cyclopentyl or X (CH
2)
m, m=0 ~ 9 wherein, X=H, OH, NH
2, Cl, F, CN, COOH, Ph or PhCH
2;
R
2represent H, CH
3(CH
3) CH, CH
3(CH
3) CHCH
2, Cyclohexyl, Cyclopentyl or Y (CH
2)
p, wherein, p=0 ~ 9, Y=H, OH, NH2, Cl, F, CN, COOH, Ph or PhCH
2;
In the preparation method of above-mentioned compound of Formula I, condensing agent used is selected from 1,3-dicyclohexylcarbodiimide (DCC), 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDCI), N, N-DIC (DIC), Vinyl chloroformate or methyl esters, solvent is selected from methylene dichloride, chloroform, tetrahydrofuran (THF), ethyl acetate, methyl acetate, 1, one or more in 2-ethylene dichloride, benzene, toluene, dioxane or DMF.
Preparation method's synthetic route of FTA derivative shown in the general formula II is as follows:
Wherein, m=0 ~ 9; X=CH, N; N=0 ~ 3, o=0 ~ 3;
R represents CH
3(CH
3) CH, CH
3(CH
3) CHCH
2, Cyclohexyl, Cyclopentyl or Y (CH
2)
p, wherein, p=0 ~ 9, Y=H, OH, NH
2, Cl, F, CN, COOH, Ph or PhCH
2;
Step comprises:
(1) compound 2 reacts and obtains compound 4 with R-Br or R-Cl under the effect of salt of wormwood or triethylamine;
(2) compound 4 reacts with methylsulfonyl chloride and obtains compound 5;
(3) compound 5 reacts with excessive ammonia and obtains compound 6;
(4) compound 6 reacts and obtains general formula II compound under condensing agent and DMAP effect with FTA, or compound 6 and FTA acyl chlorides, and under the effect of acid binding agent triethylamine or salt of wormwood, reaction obtains general formula II compound.
In above-mentioned general formula II compounds process for production thereof step (4), condensing agent is selected from 1,3-dicyclohexylcarbodiimide (DCC), 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDCI), N, N-DIC (DIC), Vinyl chloroformate or methyl esters, solvent is selected from methylene dichloride, chloroform, tetrahydrofuran (THF), ethyl acetate, methyl acetate, 1, one or more in 2-ethylene dichloride, benzene, toluene, dioxane or DMF.
The preparation synthetic route of FTA derivative shown in the general formula III is as follows:
Wherein, n=1 ~ 9;
R representative-X (CH
2)
ny, wherein X=O, NH or CH
2, n=0 ~ 8, Y=H, OH, NH
2, CN, COOH, COOMe, Cl, F, OCH
3, OCH
2cH
3, NHCH
3or NHCH
2cH
3;
Perhaps represent Ph, 2-OHPh, 2-SHPh, 2-S-farnesyl-Ph, 2-OAcPh, 2-SAcPh, 3-OHPh, 4-OHPh, 3,4-OHPh, 3,5-OHPh, 3,4,5-OHPh, 3-OMePh, 4-OMePh, 3,4-OMePh, 3,5-OMePh, 3,4,5-OMePh,
perhaps
r wherein
3=H, OH or OCH
3, R
4=H, OH or OCH
3;
Perhaps, RCO represents L-or D-type L-Ala, L-or D-type phenylalanine, L-or D-type methionine(Met), L-or D-type leucine, L-or D-type Isoleucine, L-or D-type Methionin, L-or D-type proline(Pro), L-or D-type glutamine or L-or D-type l-asparagine;
Step comprises:
(1) by compound 7 and NH
2(CH
2)
ncH
2nH
2under the effect of condensing agent, reaction obtains compound 9, or compound 7 and sulfur oxychloride or oxalyl chloride reaction are obtained to corresponding acyl chlorides directly and NH
2(CH
2)
ncH
2nH
2under the effect of acid binding agent triethylamine or salt of wormwood, reaction obtains compound 9;
(2) compound 9 reacts and obtains general formula III compound under condensing agent and DMAP effect with FTA, or compound 9 and FTA acyl chlorides, and under the effect of acid binding agent triethylamine or salt of wormwood, reaction prepares general formula III compound.
Above-mentioned preparation method's step (1) and (2) middle condensing agent for preparing general formula III compound is selected from 1,3-dicyclohexylcarbodiimide (DCC), 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDCI), N, N-DIC (DIC), Vinyl chloroformate or methyl esters.
The organic solvent that above-mentioned reaction adopts is selected from methylene dichloride, chloroform, tetrahydrofuran (THF), ethyl acetate, ethyl formate, methyl acetate, 1, one or more mixture of 2-ethylene dichloride, benzene, toluene, dioxane, DMF, preferentially adopt anhydrous methylene chloride or anhydrous tetrahydro furan or DMF.
A further object of the present invention is to provide general formula I of the present invention, II, the application of III compound in preparing the medicine for treating tumor thing.
Further purpose of the present invention is to provide a kind of pharmaceutical composition of general formula I of the present invention, II, III compound or its medically acceptable salt and pharmaceutically acceptable carrier or auxiliary material containing effective dosage.
A further object of the present invention is to provide general formula I of the present invention, II, the application of III compound in preparing antitumor drug and nerve protection medicine; especially Hepatoma therapy; carcinoma of the pancreas; lung cancer; mammary cancer; the cancer of the brain, the application in the application in the tumour medicines such as colorectal carcinoma and cancer of the stomach and brain injury nerve protection medicine.
Due to general formula I of the present invention, II, III compound, according to life science and information science latest Progress, Advanced Idea and the means of the design of application new drug are modified, are transformed the FTA structure, introduce that other pharmacophoric group obtains, it has the structure similar with FTA, can infer that from chemical structure and space structure formula I of the present invention, II and III compound have the pharmacological action of FTA.
The compounds of this invention can be made preparation for administration separately or with one or more pharmaceutically acceptable carrier combinations.For example, solvent, thinner etc., can use the oral dosage form administration, but as tablet, capsule dispersed powders, granule etc.The various formulations of pharmaceutical composition of the present invention can be prepared according to the method for knowing in pharmaceutical field.Can contain for example activeconstituents of 0.05% ~ 90% weight with carrier combinations in these medicinal preparationss, the more common approximately activeconstituents of weight between 15% ~ 60%.The compounds of this invention dosage can be 0.005 ~ 5000mg/kg/ days, also can exceed this dosage range according to the different using dosages of disease severity or formulation.
The compounds of this invention can with other antitumor drugs for example alkylating agent (as endoxan or cis-platinum), antimetabolite (as 5 FU 5 fluorouracil or hydroxyurea), topoisomerase enzyme inhibitor (as camptothecine), mitotic inhibitor (as taxol or vinealeucoblastine(VLB)), DNA intercalating agent (as Zorubicin) combined utilization, in addition can also with the radiotherapy combined utilization.These other antitumor drugs or radiotherapy can or give at different time with the compounds of this invention while.Thereby these combination therapys can produce synergy contributes to improve result for the treatment of.
The part pharmacological tests of the compounds of this invention is as follows:
1, adopt mtt assay to measure research to the Cytostatic to tumor cell rate of the compounds of this invention
Through a series of tumour cell tests, find that these general formula Is of the present invention, II, III compound are stronger to pancreatic cancer cell PANC-1 and human glioma cell U251 effect, wherein the cytoactive of most of the compounds of this invention is stronger than lead compound FTA, especially in table 4, all I and II compound inhibiting rate under 25 μ mol/L concentration all is greater than 90%, all considerably beyond primer FTA;
In human liver cancer cell Hep3B, human lung cancer cell A549 and human breast cancer cell MDA-MB-231, majority of compounds activity of the present invention is all over parent compound FTA, and in table 4, all I, II and compound III 16, III 18, III 21 inhibiting rate under 25 μ mol/L concentration is the 3-4 times of left and right of parent compound FTA;
The pharmacological results shows, the compounds of this invention has restraining effect in various degree to the propagation of human tumor cells, and the majority of compounds anti-tumor activity all significantly is better than FTA.
2, adopt flow cytometer to be detected apoptosis rate, selecting active compound I7 is representative, found that I7 has stronger cytotoxicity at 12.5 μ mol/L in to PANC-1, apoptosis rate can reach 63%, and the LO2 cell is not had to obvious restraining effect, this results suggest I7 is the apoptosis of inducing tumor cell optionally, less to normal cell injury, thereby realizes the effect of specific killing tumour cell.
3, Western blot detection of active preferably Diamines FTA derivative I 7 result that affects of carcinoma of the pancreas PANC-1 cell Bcl-2, Bax and Caspase3 protein expression is shown, the mode that Compound I 7 suppresses cell proliferation is relevant to cell death inducing, the mechanism of action of its inducing apoptosis of tumour cell is mainly that the Bax protein expression increases by impelling, Bcl-2 down-regulated expression and activate Caspase 3 vigor and activate apoptosis pathway, produces short apoptosis effect.
Above-mentioned experimental result is preferred compound I in formula I of the present invention, II and III compound
1-I
18, II
1-II
5, III
1-III
33the pharmacological results, the pharmacological effect that the present invention is met to other compounds of formula I, II and III structure also has directive significance, because formula I of the present invention, II and III compound have the chemical structure similar with FTA and space structure, thereby there is same or analogous pharmacological effect effect, through above-mentioned preferred compound I
1-I
18, II
1-II
5, III
1-III
33the checking of pharmacological evaluation, illustrate that formula I, II and III compound have anti-tumor activity.
Embodiment
In order further to illustrate the present invention, below provide a series of embodiment, these embodiment are illustrative fully, they only are used for the present invention is specifically described, and not should be understood to limitation of the present invention.The present invention FTA used is the laboratory self-control, content > 98%.
The preparation of embodiment 1 farnesyl thiosalicylic acid acyl chlorides
0.54g (1.50mmol) FTA is dissolved in to the anhydrous CH of 10mL
2cl
2in, add wherein 0.60mL (8.27mmol) sulfur oxychloride, stir 1 hour the concentrated yellow oil farnesyl thiosalicylic acid acyl chlorides that to obtain under 55 ℃.
The preparation of embodiment 2N-(2-aminoethyl) farnesyl thiosalicylic acid acid amides (I1)
0.30g (5mmol) 1,2-diaminoethane and 0.20mL (1.50mmol) triethylamine are dissolved in to the anhydrous CH of 5mL
2cl
2in, slowly drip wherein the anhydrous CH of 10mL of 0.38g (1.0mmol) farnesyl thiosalicylic acid acyl chlorides under ice bath
2cl
2solution, the 1.5h of stirring at room reaction afterwards, concentrated solvent, steam except the residue quadrol, and column chromatography obtains the 0.28g yellow oil, yield 70.5%.
1H NMR(CDCl
3,300MHz):8.00(m,1H,Ar-H),7.78(m,1H,Ar-H),7.38(m,2H,Ar-H),5.23(m,1H,SCH
2C
H),5.08(m,2H,2×CH
2C
H=CCH
3),3.56(d,2H,J=9.0Hz,SCH
2),2.99-3.05(m,4H,2×NCH
2),1.99(m,8H,2×CHC
H 2C
H 2CH),1.53-1.68(m,12H,4×CH
3);ESI-MS(m/z):401[M+H]
+。
Embodiment 3N-(3-aminopropyl) farnesyl thiosalicylic acid acid amides (I
2) preparation
With reference to embodiment 2N-(2-aminoethyl) farnesyl thiosalicylic acid acid amides (I
1) the preparation method, make faint yellow oily matter N-(3-aminopropyl) farnesyl thiosalicylic acid acid amides (I by the 1,2-diaminoethane in 1,3-propylene diamine alternative method and farnesyl thiosalicylic acid acyl chloride reaction
2), yield 70.1%.
1H NMR(CDCl
3,300MHz):7.93(m,2H,Ar-H),7.32(m,2H,Ar-H),5.21(m,1H,SCH
2C
H),5.12(m,2H,2×CH
2C
H=CCH
3),3.51(d,2H,J=9.0Hz,SCH
2),3.05(m,4H,2×NC
H 2),1.90-1.99(m,8H,2×CHC
H 2C
H 2CH),1.54-1.69(m,14H,4×CH
3,CH
2C
H 2CH
2);ESI-MS(m/z):415[M+H]
+。
Embodiment 4N-(4-ammonia butyl) farnesyl thiosalicylic acid acid amides (I
3) preparation
With reference to embodiment 2N-(2-aminoethyl) farnesyl thiosalicylic acid acid amides (I
1) the preparation method, the 1,2-diaminoethane in the Putriscine alternative method and farnesyl thiosalicylic acid acyl chloride reaction make yellow oil N-(4-ammonia butyl) farnesyl thiosalicylic acid acid amides (I
3), yield 70.3%.
1H NMR(CDCl
3,300MHz):7.96(m,2H,Ar-H),7.38(m,2H,Ar-H),5.22(m,1H,SCH
2C
H),5.12(m,2H,2×CH
2C
H=CCH
3),3.51(d,2H,J=9.0Hz,SCH
2),3.05(m,4H,2×NCH
2),1.87-1.98(m,8H,2×CHC
H 2C
H 2CH),1.52-1.78(m,16H,4×CH
3,CH
2C
H 2C
H 2CH
2);ESI-MS(m/z):429[M+H]
+。
Embodiment 5N-(5-ammonia amyl group) farnesyl thiosalicylic acid acid amides (I
4) preparation
With reference to embodiment 2N-(2-aminoethyl) farnesyl thiosalicylic acid acid amides (I
1) the preparation method, make yellow oil N-(5-ammonia amyl group) farnesyl thiosalicylic acid acid amides (I by the 1,2-diaminoethane in 1,5-pentamethylene diamine alternative method and farnesyl thiosalicylic acid acyl chloride reaction
4), yield 73.1%.
1H NMR(CDCl
3,300MHz):8.01(m,2H,Ar-H),7.32(m,2H,Ar-H),5.32(m,1H,SCH
2C
H),5.10(m,2H,2×CH
2C
H=CCH
3),3.52(d,2H,J=9.0Hz,SCH
2),3.06(m,4H,2×NCH
2),1.97-2.02(m,8H,2×CHC
H 2C
H 2CH),1.52-1.78(m,16H,4×CH
3,2×NCH
2C
H 2),1.33(m,2H,NCH
2CH
2C
H 2);ESI-MS(m/z):443[M+H]
+。
Embodiment 6N-(6-ammonia hexyl) farnesyl thiosalicylic acid acid amides (I
5) preparation
With reference to embodiment 2N-(2-aminoethyl) farnesyl thiosalicylic acid acid amides (I
1) the preparation method, make orange-yellow oily thing N-(6-ammonia hexyl) farnesyl thiosalicylic acid acid amides (I by the 1,2-diaminoethane in 1,6-hexanediamine alternative method and farnesyl thiosalicylic acid acyl chloride reaction
5), yield 84.5%.
1H NMR(CDCl
3,300MHz):δ7.37(m,3H,Ar-H),7.23(m,1H,Ar-H),5.23(m,1H,SCH
2C
H),5.09(m,2H,2×CH
2C
H=CCH
3),3.53(d,2H,J=9.0 Hz,SCH
2),3.15(m,4H,2×NCH
2),1.95-2.05(m,8H,2×CHC
H 2C
H 2CH),1.55-1.77(m,16H,4×CH3,2×NCH
2C
H 2),1.31-1.34(m,4H,2×NCH
2CH
2C
H 2);ESI-MS(m/z):457[M+H]
+。
Embodiment 7N-(3-dimethylamino-propyl) farnesyl thiosalicylic acid acid amides (I
6) preparation
With reference to embodiment 2N-(2-aminoethyl) farnesyl thiosalicylic acid acid amides (I
1) the preparation method, by N, N-dimethyl-1, the 1,2-diaminoethane in 3-propylene diamine alternative method and farnesyl thiosalicylic acid acyl chloride reaction make brown oil, yield 81.2%.
1H NMR(CDCl
3,300MHz):7.98(m,2H,Ar-H),7.31(m,2H,Ar-H),5.33(m,1H,SCH
2C
H),5.14(m,2H,2×CH
2C
H=CCH
3),3.38(d,2H,J=9.0Hz,SCH
2),3.05(m,2H,NCH
2),2.47(m,2H,NCH
2),2.24(s,6H,CH
3NCH
3),1.90-1.99(m,8H,2×CHC
H 2C
H 2CH),1.54-1.69(m,14H,4×CH
3,CH
2C
H 2C
H 2);ESI-MS(m/z):443[M+H]
+。
Embodiment 8N-(3-diethylin propyl group) farnesyl thiosalicylic acid acid amides (I
7) preparation
With reference to embodiment 2N-(2-aminoethyl) farnesyl thiosalicylic acid acid amides (I
1) the preparation method, by N, N-diethyl-1, the 1,2-diaminoethane in 3-propylene diamine alternative method and farnesyl thiosalicylic acid acyl chloride reaction make faint yellow oily matter N-(3-diethylin propyl group) farnesyl thiosalicylic acid acid amides (I
7), yield 81.2%.
1H NMR(CDCl
3,300MHz):8.08(m,1H,Ar-H),7.89(m,1H,Ar-H),7.30(m,2H,Ar-H),5.23(m,1H,SCH
2C
H),5.06(m,2H,2×CH
2C
H=CCH
3),3.48-3.42(m,4H,SCH
2,NCH
2),2.42(m,6H,3×NCH
2),1.90-1.99(m,8H,2×CHC
H 2C
H 2CH),1.54-1.69(m,14H,4×CH
3,CH
2C
H 2CH
2),0.90(m,6H,2×CH
2C
H 3);ESI-MS(m/z):471[M+H]
+。
Embodiment 9N-(3-dipropyl aminopropyl) farnesyl thiosalicylic acid acid amides (I
8) preparation
With reference to embodiment 2N-(2-aminoethyl) farnesyl thiosalicylic acid acid amides (I
1) the preparation method, 1,2-diaminoethane and farnesyl thiosalicylic acid acyl chloride reaction in the amino propylamine alternative method of 3-dipropyl make faint yellow oily matter, yield 76.8%.
1H NMR(CDCl
3,300MHz):8.02(m,1H,Ar-H),7.72(m,1H,Ar-H),7.31(m,2H,Ar-H),5.20(m,1H,SCH
2C
H),5.04(m,2H,2×CH
2C
H=CCH
3),3.50-3.44(m,4H,SCH
2,NHCH
2),2.46-2.40(m,6H,3×NCH
2),1.94-2.00(m,8H,2×CHC
H 2C
H 2CH),1.46-1.72(m,18H,4×CH=CC
H 3,CH
2C
H 2CH
2,2×C
H 2CH
3),0.89(m,6H,2×CH
2C
H 3);ESI-MS(m/z):499[M+H]
+。
Embodiment 10N-(4-dimethylamino butyl) farnesyl thiosalicylic acid acid amides (I
9) preparation
With reference to embodiment 2N-(2-aminoethyl) farnesyl thiosalicylic acid acid amides (I
1) the preparation method, the 1,2-diaminoethane in 4-dimethylamino butylamine alternative method and farnesyl thiosalicylic acid acyl chloride reaction make faint yellow oily matter N-(4-dimethylamino butyl) farnesyl thiosalicylic acid acid amides (I
9), yield 78.0%.
1H NMR(CDCl
3,300MHz):8.04(m,1H,Ar-H),7.76(m,1H,Ar-H),7.30(m,2H,Ar-H),5.24(m,1H,SCH
2C
H),5.03(m,2H,2×CH
2C
H=CCH
3),3.54-3.33(m,4H,SCH
2,NCH
2),2.47(m,2H,CH
2N),2.24(s,6H,2×NCH
3),1.94-2.00(m,8H,2×CHC
H 2C
H 2CH),1.53-1.74(m,16H,4×CH=CC
H 3,CH
2C
H 2C
H 2CH
2);ESI-MS (m/z):457[M+H]
+。
Embodiment 11N-(4-diethylin butyl) farnesyl thiosalicylic acid acid amides (I
10) preparation
With reference to embodiment 2N-(2-aminoethyl) farnesyl thiosalicylic acid acid amides (I
1) the preparation method, the 1,2-diaminoethane in 3-diethylin butylamine alternative method and farnesyl thiosalicylic acid acyl chloride reaction make yellow oil N-(4-diethylin butyl) farnesyl thiosalicylic acid acid amides (I
10), yield 71.4%.
1H NMR (CDCl
3,300MHz):7.99(m,2H,Ar-H),7.27(m,2H,Ar-H),5.32(m,1H,SCH
2C
H),5.03(m,2H,2×CH
2C
H=CCH
3),3.55(d,2H,J=9.0Hz,SCH
2),3.32(m,2H,NHC
H 2),2.42(m,6H,3×CH
2N),1.90-2.02(m,8H,2×CHC
H 2C
H 2CH),1.54-1.76(m,16H,4×CH=CC
H 3,CH
2C
H 2C
H 2CH
2),0.93(m,6H,2×CH
2C
H 3);ESI-MS(m/z):485[M+H]
+。
Embodiment 12N-(3-piperidyl propyl group) farnesyl thiosalicylic acid acid amides (I
11) preparation
With reference to embodiment 2N-(2-aminoethyl) farnesyl thiosalicylic acid acid amides (I
1) the preparation method, the 1,2-diaminoethane in 3-piperidyl propylamine alternative method and farnesyl thiosalicylic acid acyl chloride reaction make faint yellow oily matter N-(3-piperidyl propyl group) farnesyl thiosalicylic acid acid amides (I
11), yield 66.8%.
1HNMR(CDCl
3,300MHz):8.03(m,2H,Ar-H),7.32(m,2H,Ar-H),5.33(m,1H,SCH
2C
H),5.09(m,2H,2×CH
2C
H=CCH
3),3.46-3.30(m,4H,SCH
2,NCH
2),2.47(m,6H,3×NCH
2),1.90-2.02(m,8H,2×CHC
H 2C
H 2CH),1.44-1.76(m,20H,4×CH
3,4×CH
2);ESI-MS (m/z):483[M+H]
+。
Embodiment 13N-(3-pyrryl propyl group) farnesyl thiosalicylic acid acid amides (I
12) preparation
With reference to embodiment 2N-(2-aminoethyl) farnesyl thiosalicylic acid acid amides (I
1) the preparation method, the 1,2-diaminoethane in 3-pyrryl propylamine alternative method and farnesyl thiosalicylic acid acyl chloride reaction make faint yellow oily matter N-(3-pyrryl propyl group) farnesyl thiosalicylic acid acid amides (I
12), yield 69.4%.
1H NMR(CDCl
3,300MHz):8.01(m,2H,Ar-H),7.36(m,2H,Ar-H),5.38(m,1H,SCH
2C
H),5.12(m,2H,2×CH
2C
H=CCH
3),3.48-3.34(m,4H,SCH
2,NCH
2),2.52-2.40(m,6H,3×NCH
2),1.93-2.02(m,8H,2×CHC
H 2C
H 2CH),1.45-1.74(m,18H,4×CH
3,3×CH
2);ESI-MS(m/z):469[M+H]
+。
Embodiment 14N-(3-(4-methylpiperazine-1-yl) propyl group) farnesyl thiosalicylic acid acid amides (I
13) preparation
With reference to embodiment 2N-(2-aminoethyl) farnesyl thiosalicylic acid acid amides (I
1) the preparation method, 1,2-diaminoethane in 3-(4-methylpiperazine-1-yl) propylamine alternative method and farnesyl thiosalicylic acid acyl chloride reaction make faint yellow oily matter N-(3-(4-methylpiperazine-1-yl) propyl group) farnesyl thiosalicylic acid acid amides (I
13), yield 66.8%.
1H NMR(CDCl
3,300MHz):8.01(m,1H,Ar-H),7.56(m,1H,Ar-H),7.36(m,2H,Ar-H),5.32(m,1H,SCH
2C
H),5.01(m,2H,2×CH
2C
H=CCH
3),3.52-3.40(m,4H,SCH
2,CONCH
2),2.57(3H,s,NCH
3),2.49-2.36(m,10H,5×NCH
2),1.89-2.01(m,8H,2×CHC
H 2C
H 2CH),1.50-1.74(m,14H,4×CH
3,C
H 2C
H 2CH
2);ESI-MS (m/z):484[M+H]
+。
Embodiment 15N-(4-piperidyl butyl) farnesyl thiosalicylic acid acid amides (I
14) preparation
With reference to embodiment 2N-(2-aminoethyl) farnesyl thiosalicylic acid acid amides (I
1) the preparation method, the 1,2-diaminoethane in 4-piperidyl butylamine alternative method and farnesyl thiosalicylic acid acyl chloride reaction make faint yellow oily matter N-(4-piperidyl butyl) farnesyl thiosalicylic acid acid amides (I
14), yield 69.1%.
1H NMR(CDCl
3,300MHz):8.01(m,2H,Ar-H),7.30(m,2H,Ar-H),5.38(m,1H,SCH
2C
H),5.12(m,2H,2×CH
2C
H=CCH
3),3.49-3.33(m,4H,SCH
2,NCH
2),3.52-2.39(m,6H,3×CH
2N),1.90-2.04(m,8H,2×CHC
H 2C
H 2CH),1.46-1.75(m,22H,4×CH
3,5×CH
2);ESI-MS(m/z):497[M+H]
+;
Embodiment 16N-(4-pyrryl butyl) farnesyl thiosalicylic acid acid amides (I
15) preparation
With reference to embodiment 2N-(2-aminoethyl) farnesyl thiosalicylic acid acid amides (I
1) the preparation method, the 1,2-diaminoethane in 4-pyrryl butylamine alternative method and farnesyl thiosalicylic acid acyl chloride reaction make faint yellow oily matter N-(4-pyrryl butyl) farnesyl thiosalicylic acid acid amides (I
15), yield 70.7%.
1H NMR(CDCl
3,300MHz):
8.03(m,2H,Ar-H),7.36(m,2H,Ar-H),5.32(m,1H,SCH
2C
H),5.11(m,2H,2×CH
2C
H=CCH
3),3.46-3.31(m,4H,SCH
2,NCH
2),2.56-2.41(m,6H,3×CH
2N),1.91-2.03(m,8H,2×CHC
H 2C
H 2CH),1.52-1.74(m,20H,4×CH
3,4×CH
2);ESI-MS(m/z):483[M+H]
+。
Embodiment 17N-(morpholinyl propyl group) farnesyl thiosalicylic acid acid amides (I
16) preparation
With reference to embodiment 2N-(2-aminoethyl) farnesyl thiosalicylic acid acid amides (I
1) the preparation method, the 1,2-diaminoethane in morpholinyl propylamine alternative method and farnesyl thiosalicylic acid acyl chloride reaction make yellow oil N-(morpholinyl propyl group) farnesyl thiosalicylic acid acid amides (I
16), yield 69.8%.
1H NMR(CDCl
3,300MHz):
7.96(m,1H,Ar-H),7.52(m,1H,Ar-H),7.31(m,2H,Ar-H),5.30(m,1H,SCH
2C
H),5.02(m,2H,2×CH
2C
H=CCH
3),3.78(m,4H,CH
2OCH
2),3.50-3.26(m,4H,SCH
2,CONCH
2),2.49-2.33(m,6H,3×CH
2N),1.92-2.01(m,8H,2×CHC
H 2C
H 2CH),1.52-1.77(m,14H,4×CH
3,CH
2C
H 2CH
2);ESI-MS (m/z):485[M+H]
+。
Embodiment 18N-(3-(N, N-dihydroxy ethyl)-aminopropyl) farnesyl thiosalicylic acid acid amides (I
17) preparation
With reference to embodiment 2N-(2-aminoethyl) farnesyl thiosalicylic acid acid amides (I
1) the preparation method, by 3-(N, the N-dihydroxy ethyl) 1,2-diaminoethane in-amino propylamine alternative method and farnesyl thiosalicylic acid acyl chloride reaction make faint yellow oily matter N-(3-(N, N-dihydroxy ethyl)-aminopropyl) farnesyl thiosalicylic acid acid amides (I
17), yield 73.4%.
1H NMR(CDCl
3,300MHz):7.91(m,1H,Ar-H),7.50(m,1H,Ar-H),7.35(m,2H,Ar-H),5.41(m,1H,SCH
2C
H),5.12(m,2H,2×CH
2C
H=CCH
3),3.66(m,2H,2×OH),3.51-3.30(m,8H,SCH
2,CONCH
2,2×C
H 2OH),2.69-2.53(m,6H,3×NCH
2),1.92-2.01(m,8H,2×CHC
H 2C
H 2CH),1.52-1.77(m,14H,4×CH
3,CH
2C
H 2CH
2);ESI-MS(m/z):503[M+H]
+。
Embodiment 19N-(2-(N-hydroxyethyl)-amino-ethyl) farnesyl thiosalicylic acid acid amides (I
18) preparation
With reference to embodiment 2N-(2-aminoethyl) farnesyl thiosalicylic acid acid amides (I
1) the preparation method, 1,2-diaminoethane in 2-(N-hydroxyethyl)-aminoethyl alternative method and farnesyl thiosalicylic acid acyl chloride reaction make faint yellow oily matter N-(2-(N-hydroxyethyl)-amino-ethyl) farnesyl thiosalicylic acid acid amides (I
18), yield 73.4%.
1H NMR(CDCl
3,300MHz):δ7.37(m,3H,Ar-H),7.26(m,1H,Ar-H),5.23(m,1H,SCH
2C
H),5.08(m,2H,2×CH
2C
H=CCH
3),3.56(d,2H,J=9.0Hz,SCH
2),3.10-3.31(m,4H,CONCH
2,C
H 2OH),2.51(m,4H,CH
2NCH
2),1.99(m,8H,2×CHC
H 2C
H 2CH),1.60-1.79(m,12H,4×CH=CC
H 3);ESI-MS(m/z):445[M+H]
+。
Embodiment 20N-(2-(1-benzyl piepridine-4-yl) ethyl) farnesyl thiosalicylic acid acid amides (II
1) preparation
(1) preparation of 2-(1-benzyl piepridine-4-yl) ethanol (4a)
0.13g (1.00mmol) 4-hydroxyethyl piperidine and 0.17g (1.00mmol) bromobenzyl are dissolved in to 20mLCH
2cl
2, add wherein 0.21g (1.51mmol) K
2cO
3at room temperature stir 10h, steaming desolventizes, and 30mL acetic acid ethyl dissolution residual solid, wash with 50mL, use again ethyl acetate (50mL * 2) aqueous layer extracted, merge organic phase, drying, filter, become a cadre and obtain 0.18g oily matter 2-(1-benzyl piepridine-4-yl) ethanol (4a), yield 82.2%;
(2) preparation of 2-(1-benzyl piepridine-4-yl) ethyl methane sulfonate (5a)
0.22g (1.00mmol) compound 4a is dissolved in to the anhydrous CH of 10mL
2cl
2, slowly drip wherein the anhydrous CH of 5mL of 0.14g (1.22mmol) MsCl under ice bath
2cl
2solution, dropwise rear stirring at room 1.5h, steaming desolventizes, and 30mL acetic acid ethyl dissolution residual solid, wash with 50mL, use again ethyl acetate (50mL * 2) aqueous layer extracted, merge organic phase, drying, filter, become a cadre and obtain 0.23g oily matter 2-(1-benzyl piepridine-4-yl) ethyl methane sulfonate (5a), yield 77.4%;
(3) preparation of 2-(1-benzyl piepridine-4-yl) ethamine (6a)
0.2g (0.67mmol) compound 5a is added in 10mL ammoniacal liquor, stirring at room 24h, reaction solution directly concentrated becoming a cadre obtains 0.15g oily matter 2-(1-benzyl piepridine-4-yl) ethamine (6a), yield 75.3%;
(4) N-(2-(1-benzyl piepridine-4-yl) ethyl) farnesyl thiosalicylic acid acid amides (II
1) preparation
0.22g (1.0mmol) compound 6a and 0.15g (1.5mmol) triethylamine are dissolved in to the anhydrous CH of 15mL
2cl
2, slowly drip wherein the anhydrous CH of 5mL of 0.38g (1.01mmol) farnesyl thiosalicylic acid acyl chlorides under ice bath
2cl
2solution, then stirring at room 1.5h, steaming desolventizes and remains triethylamine, and 50mL acetic acid ethyl dissolution residual solid, wash with 50mL, use again ethyl acetate (50mL * 2) aqueous layer extracted, merge organic phase, drying, filter, become a cadre, column chromatography obtains 0.38g oily matter N-(2-(1-benzyl piepridine-4-yl) ethyl) farnesyl thiosalicylic acid acid amides (II
1), yield 68.1%.
1H NMR(CDCl
3,300MHz):8.00(m,1H,Ar-H),7.78(m,1H,Ar-H),7.38(m,2H,Ar-H),7.27(m,2H,Ar-H),6.94(m,2H,Ar-H),6.78(m,1H,Ar-H),5.24(m,1H,SCH
2C
H),5.02(m,2H,2×CH
2C
H=CCH
3),3.68(s,2H,NCH
2),3.56(d,2H,J=9.0Hz,SCH
2),3.32-3.45(m,2H,NCH
2),3.01-2.99(m,4H,CH
2NCH
2),1.99-2.01(m,8H,2×CHC
H 2C
H 2CH),1.53-1.68(m,19H,4×CH=CC
H 3,CH,3×NCH
2C
H 2);ESI-MS(m/z):559[M+H]
+。
Embodiment 21N-(2-(1-benzyl piepridine-4-yl) methyl) farnesyl thiosalicylic acid acid amides (II
2) preparation
(1) preparation of 2-(1-benzyl piepridine-4-yl) methyl alcohol (4b)
With reference to the preparation method of embodiment 20 steps (1) compound 4a, the 4-hydroxyethyl piperidine in 4-hydroxymethyl piperidine alternative method and bromobenzyl reaction make oily matter 2-(1-benzyl piepridine-4-yl) methyl alcohol (4b), yield 70.2%;
(2) preparation of 2-(1-benzyl piepridine-4-yl) methyl mesylate (5b)
With reference to the preparation method of embodiment 20 steps (2) compound 5a, the compound 4a in compound 4b alternative method and MsCl reaction make oily matter 2-(1-benzyl piepridine-4-yl) methyl mesylate (5b), yield 67.6%;
(3) preparation of 2-(1-benzyl piepridine-4-yl) methylamine (6b)
With reference to the preparation method of embodiment 20 steps (3) compound 6a, the compound 5a in compound 5b alternative method makes oily matter 2-(1-benzyl piepridine-4-yl) methylamine (6b), yield 81.2% under the ammoniacal liquor effect;
(4) N-(2-(1-benzyl piepridine-4-yl) methyl) farnesyl thiosalicylic acid acid amides (II
2) preparation
With reference to embodiment 20 steps (4) compound ii
1the preparation method, the compound 6a in compound 6b alternative method and farnesyl thiosalicylic acid acyl chloride reaction make oily matter N-(2-(1-benzyl piepridine-4-yl) methyl) farnesyl thiosalicylic acid acid amides (II
2), yield 71.3%.
1H NMR(CDCl
3,300MHz):8.01(m,1H,Ar-H),7.72(m,1H,Ar-H),7.38(m,2H,Ar-H),7.26(m,2H,Ar-H),6.97(m,2H,Ar-H),6.72(m,1H,Ar-H),5.22(m,1H,SCH
2C
H),5.02(m,2H,2×CH
2C
H=CCH
3),3.68(s,2H,NCH
2),3.57(d,2H,J=9.0Hz,SCH
2),3.32(m,2H,NCH
2),3.02-2.99(m,4H,CH
2NCH
2),1.99-2.01(m,8H,2×CHC
H 2C
H 2CH),1.53-1.68(m,17H,4×CH=CC
H 3,CH,2×NCH
2C
H 2);ESI-MS(m/z):545[M+H]
+。
Embodiment 22N-(2-(1-ethyl piperidine-4-yl) ethyl) farnesyl thiosalicylic acid acid amides (II
3) preparation
(1) preparation of 2-(1-ethyl piperidine-4-yl) ethanol (4c)
Preparation method with reference to embodiment 20 steps (1) compound 4a, 4-hydroxyethyl piperidine in 4-hydroxyethyl piperidine alternative method, bromobenzyl reaction in the bromic ether alternative method makes oily matter 2-(1-ethyl piperidine-4-yl) ethanol (4c), yield 71.2%;
(2) preparation of 2-(1-ethyl piperidine-4-yl) ethyl methane sulfonate (5c)
With reference to the preparation method of embodiment 20 steps (2) compound 5a, the compound 4a in compound 4c alternative method and MsCl reaction make oily matter 2-(1-ethyl piperidine-4-yl) ethyl methane sulfonate (5c), yield 72.1%;
(3) preparation of 2-(1-ethyl piperidine-4-yl) ethamine (6c)
With reference to the preparation method of embodiment 20 steps (3) compound 6a, the compound 5a in compound 5c alternative method makes oily matter 2-(1-ethyl piperidine-4-yl) ethamine (6c), yield 87.1% under the ammoniacal liquor effect;
(4) N-(2-(1-ethyl piperidine-4-yl) ethyl) farnesyl thiosalicylic acid acid amides (II
3)
With reference to embodiment 20 steps (4) compound ii
1the preparation method, the compound 6a in compound 6c alternative method and farnesyl thiosalicylic acid acyl chloride reaction make oily matter N-(2-(1-ethyl piperidine-4-yl) ethyl) farnesyl thiosalicylic acid acid amides (II
3), yield 73.4%;
1H NMR(CDCl
3,300MHz):8.00(m,1H,Ar-H),7.68(m,1H,Ar-H),7.40(m,2H,Ar-H),5.32(m,1H,SCH
2C
H),5.11(m,2H,2×CH
2C
H=CCH
3),3.59(d,2H,J=9.0Hz,SCH
2),3.42(m,2H,NCH
2),3.00-2.69(m,4H,3×NCH
2),1.99-2.01(m,8H,2×CHC
H 2C
H 2CH),1.50-1.68(m,19H,4×CH=CC
H 3,CH,3×NCH
2C
H 2),1.01(m,3H,CH
3);ESI-MS(m/z):497[M+H]
+。
Embodiment 23N-(2-(1-benzyl diethylenediamine-4-yl) ethyl) farnesyl thiosalicylic acid acid amides (II
4)
(1) preparation of 2-(1-benzyl diethylenediamine-4-yl) ethanol (4d)
With reference to the preparation method of embodiment 20 steps (1) compound 4a, the 4-hydroxyethyl piperidine in the hydroxyethyl piperazine alternative method and bromobenzyl reaction make oily matter 2-(1-benzyl diethylenediamine-4-yl) ethanol (4d, yield 65.3%;
(2) preparation of 2-(1-benzyl diethylenediamine-4-yl) ethyl methane sulfonate (5d)
With reference to the preparation method of embodiment 20 steps (2) compound 5a, the 4a in compound 4d alternative method and MsCl reaction make oily matter 2-(1-benzyl diethylenediamine-4-yl) ethyl methane sulfonate (5d), yield 82.1%;
(3) preparation of 2-(1-benzyl diethylenediamine-4-yl) ethamine (6d)
With reference to the preparation method of embodiment 20 steps (3) compound 6a, the 5a in compound 5d alternative method makes oily matter 2-(1-benzyl diethylenediamine-4-yl) ethamine (6d), yield 82.7% under the ammoniacal liquor effect;
(4) N-(2-(1-benzyl diethylenediamine-4-yl) ethyl) farnesyl thiosalicylic acid acid amides (II
4) preparation
With reference to embodiment 20 steps (4) compound ii
1the preparation method, the 6a in compound 6d alternative method and farnesyl thiosalicylic acid acyl chloride reaction make oily matter N-(2-(1-benzyl diethylenediamine-4-yl) ethyl) farnesyl thiosalicylic acid acid amides (II
4), yield 68.4%.
1H NMR(CDCl
3,300MHz):8.01(m,1H,Ar-H),7.72(m,1H,Ar-H),7.39(m,2H,Ar-H),7.26(m,2H,Ar-H),6.97(m,2H,Ar-H),6.72(m,1H,Ar-H),5.31(m,1H,SCH
2C
H),5.01(m,2H,2×CH
2C
H=CCH
3),3.67(s,2H,NCH
2),3.57(d,2H,J=9.0Hz,SCH
2),3.32(m,2H,NCH
2),2.67-2.39(m,10H,5×NCH
2),1.98-2.03(m,8H,2×CHC
H 2C
H 2CH),1.53-1.69(m,12H,4×CH
3);ESI-MS(m/z):560[M+H]
+。
Embodiment 24N-(2-(1-ethyl piperazidine-4-yl) ethyl) farnesyl thiosalicylic acid acid amides (II
5)
(1) preparation of 2-(1-ethyl piperazidine-4-yl) ethanol (4e)
With reference to the preparation method of embodiment 20 steps (1) 4a, the 4-hydroxyethyl piperidine in the hydroxyethyl piperazine alternative method, the bromobenzyl reaction in the bromic ether alternative method makes oily matter 2-(1-ethyl piperazidine-4-yl) ethanol (4e), yield 65.3%;
(2) preparation of 2-(1-ethyl piperazidine-4-yl) ethyl methane sulfonate (5e)
With reference to the preparation method of embodiment 20 steps (2) 5a, the 4a in compound 4e alternative method and MsCl reaction make oily matter 2-(1-ethyl piperazidine-4-yl) ethyl methane sulfonate (5e), yield 82.1%;
(3) preparation of 2-(1-ethyl piperazidine-4-yl) ethamine (6e)
With reference to the preparation method of embodiment 20 steps (3) 6a, the 5a in compound 5e alternative method makes oily matter 2-(1-ethyl piperazidine-4-yl) ethamine (6e), yield 82.7% under the ammoniacal liquor effect;
(4) N-(2-(1-ethyl piperazidine-4-yl) ethyl) farnesyl thiosalicylic acid acid amides (II
5) preparation
With reference to embodiment 20 steps (4) compound ii
1the preparation method, the 6a in compound 6e alternative method and farnesyl thiosalicylic acid acyl chloride reaction make oily matter N-(2-(1-ethyl piperazidine-4-yl) ethyl) farnesyl thiosalicylic acid acid amides (II
5), yield 79.3%.
1H NMR(CDCl
3,300MHz):8.00(m,1H,Ar-H),7.76(m,1H,Ar-H),7.40(m,2H,Ar-H),7.26(m,2H,Ar-H),6.96(m,2H,Ar-H),6.70(m,1H,Ar-H),5.28(m,1H,SCH
2C
H),5.10(m,2H,2×CH
2C
H=CCH
3),3.58(d,2H,J=9.0Hz,SCH
2),3.45(m,2H,NCH
2),2.67-2.39(m,12H,6×NCH
2),1.99-2.00(m,8H,2×CHC
H 2C
H 2CH),1.53-1.68(m,12H,4×CH=CC
H 3),1.03(m,3H,CH
3);ESI-MS(m/z):498[M+H]
+。
Embodiment 25N-(2-(Aspirin amide group) ethyl) farnesyl thiosalicylic acid acid amides (III
1) preparation
(1) preparation of N-(2-amino-ethyl)-Aspirin acid amides (9a)
1.5g (25.00mmol) 1,2-diaminoethane and 0.76g (7.52mmol) triethylamine are dissolved in to the anhydrous CH of 30mL
2cl
2, slowly drip wherein the anhydrous CH of 20mL of 1g (5.05mmol) acetylsalicylic acid acyl chlorides under 0-5 ℃
2cl
2solution, drip complete stirring at room 1.5h, and steaming desolventizes, triethylamine and excessive 1,2-diaminoethane, and column chromatography obtains 0.90g yellow oil N-(2-amino-ethyl)-Aspirin acid amides (9a), yield 81.1%;
(2) N-(2-(Aspirin amide group) ethyl) farnesyl thiosalicylic acid acid amides (III
1) preparation
0.12g (0.54mmol) compound 9a and 0.071g (0.70mmol) triethylamine are dissolved in the 5mL dry DMF, drip the anhydrous CH of 10mL of 0.18g (0.48mmol) farnesyl thiosalicylic acid acyl chlorides under ice bath
2cl
2solution, drip complete stirring at room 2h, steams and desolventize and remain triethylamine, and column chromatography obtains 0.19g yellow oil N-(2-(Aspirin amide group) ethyl) farnesyl thiosalicylic acid acid amides (III
1), yield 70.4%.
1H NMR(CDCl
3,300MHz):8.01(s,1H,Ar-H),7.75(d,1H,J=6.0Hz,Ar-H),7.39(m,4H,Ar-H),7.27(m,2H,Ar-H),6.86(m,1H,NH),5.76(m,1H,NH),5.21(m,1H,SCH
2C
H),5.13(m,2H,2×CH
2C
H=CCH
3),3.71(m,2H,2×NCH
2),3.51(d,2H,J=9.0Hz,SCH
2),2.62(s,3H,COCH
3),1.95-2.05(m,8H,2×CHC
H 2C
H 2CH),1.51-1.77(m,12H,4×CH=CC
H 3);ESI-MS (m/z):547[M+H]
+。
Embodiment 26N-(3-(Aspirin amide group) propyl group) farnesyl thiosalicylic acid acid amides (III
2) preparation
(1) preparation of N-(3-aminopropyl)-Aspirin acid amides (9b)
Preparation method with reference to embodiment 25 steps (1) compound 9a, by 1,1,2-diaminoethane in 3-propylene diamine alternative method and acetylsalicylic acid acyl chloride reaction make faint yellow oily matter N-(3-aminopropyl)-Aspirin acid amides (9b), yield 77.2%;
(2) N-(3-(Aspirin amide group) propyl group) farnesyl thiosalicylic acid acid amides (III
2) preparation
With reference to embodiment 25 steps (2) compound III
1the preparation method, the 9a in compound 9b alternative method and farnesyl thiosalicylic acid acyl chloride reaction make yellow transparent oily matter N-(3-(Aspirin amide group) propyl group) farnesyl thiosalicylic acid acid amides (III
2), yield 67.4%.
1H NMR(CDCl
3,300MHz):8.01(s,1H,Ar-H),7.66(d,1H,J=6.0Hz,Ar-H),7.31(m,4H,Ar-H),7.22(m,2H,Ar-H),6.96(m,1H,NH),5.86(m,1H,NH),5.22(m,1H,SCH
2C
H),5.01(m,2H,2×CH
2C
H=CCH
3),3.54(d,2H,J=9.0Hz,SCH
2),3.40-3.30(m,2H,2×NCH
2),2.78(s,3H,COCH
3),1.93-2.03(m,10H,2×CHC
H 2C
H 2CH,CH
2C
H 2CH
2),1.51-1.77(m,12H,4×CH=CC
H 3);ESI-MS(m/z):561[M+H]
+。
Embodiment 27N-(4-(Aspirin amide group) butyl) farnesyl thiosalicylic acid acid amides (III
3) preparation
(1) preparation of N-(4-aminobutyl)-Aspirin acid amides (9c)
Preparation method with reference to embodiment 25 steps (1) compound 9a, by 1,1,2-diaminoethane in 4-butanediamine alternative method and acetylsalicylic acid acyl chloride reaction make faint yellow oily matter N-(4-aminobutyl)-Aspirin acid amides (9c), yield 79.0%;
(2) N-(4-(Aspirin amide group) butyl) farnesyl thiosalicylic acid acid amides (III
3) preparation
With reference to embodiment 25 steps (1) compound III
1the preparation method, the 9a in compound 9c alternative method and farnesyl thiosalicylic acid acyl chloride reaction make yellow transparent oily matter N-(4-(Aspirin amide group) butyl) farnesyl thiosalicylic acid acid amides (III
3), yield 73.2%.
1H NMR(CDCl
3,300MHz):8.06(s,1H,Ar-H),7.71(d,1H,J=6.0Hz,Ar-H),7.42(m,2H,Ar-H),7.30(m,2H,Ar-H),7.22(m,2H,Ar-H),6.82(m,1H,NH),5.61(m,1H,NH),5.22(m,1H,SCH
2C
H),5.03(m,2H,2×CH
2C
H=CCH
3),3.50(d,2H,J=9.0 Hz,SCH
2),3.35(m,2H,2×NCH
2),2.82(s,3H,COCH
3),1.92-2.01(m,10H,2×CHC
H 2C
H 2CH),1.51-1.77(m,16H,4×CH=CC
H 3,2×CH
2);ESI-MS(m/z):575[M+H]
+。
Embodiment 28N-(5-(Aspirin amide group) amyl group) farnesyl thiosalicylic acid acid amides (III
4) preparation
(1) preparation of N-(the amino amyl group of 5-)-Aspirin acid amides (9d)
Preparation method with reference to embodiment 25 steps (1) compound 9a, by 1,1,2-diaminoethane in 5-pentamethylene diamine alternative method and acetylsalicylic acid acyl chloride reaction make faint yellow oily matter N-(the amino amyl group of 5-)-Aspirin acid amides (9d), yield 75.7%;
(2) N-(5-(Aspirin amide group) amyl group) farnesyl thiosalicylic acid acid amides (III
4) preparation
With reference to embodiment 25 steps (2) compound III
1the preparation method, the 9a in compound 9d alternative method and farnesyl thiosalicylic acid acyl chloride reaction make yellow transparent oily matter N-(5-(Aspirin amide group) amyl group) farnesyl thiosalicylic acid acid amides (III
4), yield 68.3%.
1H NMR(CDCl
3,300MHz):8.02(s,1H,Ar-H),7.62(d,1H,J=6.0Hz,Ar-H),7.43(m,2H,Ar-H),7.32(m,2H,Ar-H),7.21(m,2H,Ar-H),6.82(m,1H,NH),5.69(m,1H,NH),5.20(m,1H,SCH
2C
H),5.04(m,2H,2×CH
2C
H=CCH
3),3.53(d,2H,J=9.0 Hz,SCH
2),3.42(m,2H,2×NCH
2),2.75(s,3H,COCH
3),1.87-2.02(m,8H,2×CHC
H 2C
H 2CH),1.52-1.74(m,16H,4×CH=CC
H 3,2×CH
2),1.40(m,2H,CH
2);ESI-MS(m/z):589[M+H]
+。
Embodiment 29N-(6-(Aspirin amide group) hexyl) farnesyl thiosalicylic acid acid amides (III
5) preparation
(1) preparation of N-(the amino hexyl of 6-)-Aspirin acid amides (9e)
Preparation method with reference to embodiment 25 steps (1) compound 9a, by 1,1,2-diaminoethane in 6-hexanediamine alternative method and acetylsalicylic acid acyl chloride reaction make yellow oil N-(the amino hexyl of 6-)-Aspirin acid amides (9e), yield 83.4%;
(2) N-(6-(Aspirin amide group) hexyl) farnesyl thiosalicylic acid acid amides (III
5) preparation
With reference to embodiment 25 steps (2) compound III
1the preparation method, the 9a in compound 9d alternative method and farnesyl thiosalicylic acid acyl chloride reaction make yellow transparent oily matter N-(6-(Aspirin amide group) hexyl) farnesyl thiosalicylic acid acid amides (III
5), yield 68.3%.
1H NMR(CDCl
3,300MHz):8.02(s,1H,Ar-H),7.65(d,1H,J=6.0Hz,Ar-H),7.39(m,2H,Ar-H),7.33(m,2H,Ar-H),7.26(m,2H,Ar-H),6.86(m,1H,NH),5.76(m,1H,NH),5.26(m,1H,SCH
2C
H),5.10(m,2H,2×CH
2C
H=CCH
3),3.52(d,2H,J=9.0 Hz,SCH
2),3.48(m,2H,NCH
2),3.25(m,2H,NCH
2),2.88(s,3H,COCH
3),1.97-2.03(m,8H,2×CHC
H 2C
H 2CH),1.50-1.75(m,16H,4×CH=CC
H 3,2×NCH
2C
H 2),1.41(m,4H,CH
2CH
2);ESI-MS (m/z):603[M+H]
+。
Embodiment 30N-(2-(3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides base) ethyl) farnesyl thiosalicylic acid acid amides (III
6) preparation
(1) preparation of N-(2-amino-ethyl)-3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides (9k)
Preparation method with reference to embodiment 25 steps (1) compound 9a, acetylsalicylic acid acyl chlorides and 1 in 3-(3-methoxyl group-4-acetoxyl group phenyl) vinylformic acid acyl chlorides alternative method, 2-quadrol and reaction make glassy yellow solid N-(2-amino-ethyl)-3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides (9k), yield 83.6%;
(2) N-(2-(3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides base) ethyl) farnesyl thiosalicylic acid acid amides (III
6) preparation
With reference to the preparation method of embodiment 25 steps (2) compound III 1, the 9a in compound 9k alternative method and farnesyl thiosalicylic acid acyl chlorides make yellow oil N-(2-(3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides base) ethyl) farnesyl thiosalicylic acid acid amides (III
6), yield 70.2%.
1H NMR(CDCl
3,300MHz):8.00(s,1H,Ar-H),7.58-7.67(m,2H,Ar-H),7.55(d,1H,NH),7.33(m,2H,Ar-H),7.01(m,2H,Ar-H),6.86-6.83(m,1H,J=9Hz,COCH=C
H),6.25-6.20(d,1H,J=15Hz,COC
H=CH),5.80(m,1H,NH),5.27(m,1H,SCH
2C
H),5.01(m,2H,2×CH
2C
H=CCH
3),3.85(s,3H,OCH
3),3.42-3.56(m,6H,SCH
2,2×NCH
2),2.88(s,3H,COCH
3),1.97-2.02(m,8H,2×CHC
H 2C
H 2CH),1.50-1.71(m,12H,4×CH=CC
H 3);ESI-MS(m/z):619[M+H]
+。
Embodiment 31N-(3-(3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides base) propyl group) farnesyl thiosalicylic acid acid amides (III
7) preparation
(1) preparation of N-(3-aminopropyl)-3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides (9l)
Preparation method with reference to embodiment 25 steps (1) compound 9a, by 1, in 3-propylene diamine and 3-(3-methoxyl group-4-acetoxyl group phenyl) vinylformic acid acyl chlorides alternative method 1,2-quadrol and acetylsalicylic acid acyl chloride reaction make glassy yellow solid N-(3-aminopropyl)-3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides (9l), yield 86.1%;
(2) N-(3-(3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides base) propyl group) farnesyl thiosalicylic acid acid amides (III
7) preparation
With reference to embodiment 25 steps (2) compound III
1the preparation method, the 9a in compound 9l alternative method and farnesyl thiosalicylic acid acyl chloride reaction make yellow oil N-(3-(3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides base) propyl group) farnesyl thiosalicylic acid acid amides (III
7), yield 64.8%.
1H NMR(CDCl
3,300MHz):8.02(s,1H,Ar-H),7.51-7.67(m,2H,Ar-H,NH),7.32(m,2H,Ar-H),7.11(m,2H,Ar-H),6.96-6.93(m,1H,J=9Hz,COCH=C
H),6.26-6.21(d,1H,J=15Hz,COC
H=CH),5.86(m,1H,NH),5.23(m,1H,SCH
2C
H),5.02(m,2H,2×CH
2C
H=CCH
3),3.83(s,3H,OCH
3),3.45-3.52(m,6H,SCH
2,2×NCH
2),2.82(s,3H,COCH
3),1.90-2.02(m,10H,2×CHC
H 2C
H 2CH,CH
2),1.50-1.71(m,12H,4×CH=CC
H 3);ESI-MS(m/z):633[M+H]
+。
Embodiment 32N-(4-(3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides base) butyl) farnesyl thiosalicylic acid acid amides (III
8) preparation
(1) preparation of N-(4-aminobutyl)-3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides (9m)
Preparation method with reference to embodiment 25 steps (1) compound 9a, by 1, in 4-butanediamine and 3-(3-methoxyl group-4-acetoxyl group phenyl) vinylformic acid acyl chlorides alternative method 1,2-quadrol and acetylsalicylic acid acyl chloride reaction make yellow oil N-(4-aminobutyl)-3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides (9m), yield 77.3%;
(2) N-(4-(3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides base) butyl) farnesyl thiosalicylic acid acid amides (III
8) preparation
With reference to embodiment 25 steps (2) compound III
1the preparation method, the 9a in compound 9m alternative method and farnesyl thiosalicylic acid acyl chloride reaction make glassy yellow oily matter N-(4-(3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides base) butyl) farnesyl thiosalicylic acid acid amides (III
8), yield 70.2%.
1H NMR(CDCl
3,300MHz):8.01(s,1H,Ar-H),7.48-7.63(m,2H,Ar-H,NH),7.30(m,2H,Ar-H),7.12(m,2H,Ar-H),6.96-6.93(m,1H,J=9Hz,COCH=C
H),6.23-6.18(d,1H,J=15Hz,COC
H=CH),5.83(m,1H,NH),5.22(m,1H,SCH
2C
H),5.05(m,2H,2×CH
2C
H=CCH
3),3.82(s,3H,OCH
3),3.50-3.41(m,6H,SCH
2,2×NCH
2),2.80(s,3H,COCH
3),1.90-2.02(m,8H,2×CHC
H 2C
H 2CH),1.50-1.75(m,16H,4×CH=CCH3,CH
2C
H 2C
H 2CH
2);ESI-MS(m/z):647[M+H]
+。
Embodiment 33N-(5-(3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides base) amyl group) farnesyl thiosalicylic acid acid amides (III
9) preparation
(1) preparation of N-(the amino amyl group of 5-)-3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides (9n)
Preparation method with reference to embodiment 25 steps (1) compound 9a, by 1, in 5-pentamethylene diamine and 3-(3-methoxyl group-4-acetoxyl group phenyl) vinylformic acid acyl chlorides alternative method 1,2-quadrol and acetylsalicylic acid acyl chloride reaction make yellow oil N-(the amino amyl group of 5-)-3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides (9n), yield 80.3%;
(2) N-(5-(3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides base) amyl group) farnesyl thiosalicylic acid acid amides (III
9) preparation
With reference to embodiment 25 steps (2) compound III
1the preparation method, the 9a in compound 9n alternative method and farnesyl thiosalicylic acid acyl chloride reaction make faint yellow oily matter N-(5-(3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides base) amyl group) farnesyl thiosalicylic acid acid amides (III
9), yield 65.6%.
1H NMR(CDCl
3,300MHz):8.02(s,1H,Ar-H),7.53-7.70(m,2H,Ar-H,NH),7.35(m,2H,Ar-H),7.11(m,2H,Ar-H),6.94-6.91(m,1H,J=9Hz,COCH=C
H),6.25-6.20(d,1H,J=15Hz,COC
H=CH),5.80(m,1H,NH),5.31(m,1H,SCH
2C
H),5.11(m,2H,2×CH
2C
H=CCH
3),3.73(s,3H,OCH
3),3.52-3.40(m,6H,SCH
2,2×NCH
2),2.83(s,3H,COCH
3),1.94-2.00(m,8H,2×CHC
H 2C
H 2CH),1.50-1.75(m,16H,4×CH=CC
H 3,2×CH
2),1.41(m,2H,CH
2);ESI-MS(m/z):647[M+H]
+。
Embodiment 33N-(6-(3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides base) hexyl) farnesyl thiosalicylic acid acid amides (III
10) preparation
(1) preparation of N-(the amino hexyl of 6-)-3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides (9o)
Preparation method with reference to embodiment 25 steps (1) compound 9a, by 1, in 6-hexanediamine and 3-(3-methoxyl group-4-acetoxyl group phenyl) vinylformic acid acyl chlorides alternative method 1,2-quadrol and acetylsalicylic acid acyl chloride reaction make yellow oil N-(the amino hexyl of 6-)-3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides (9o), yield 80.3%;
(2) N-(6-(3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides base) hexyl) farnesyl thiosalicylic acid acid amides (III
10) preparation
With reference to embodiment 25 steps (2) compound III
1the preparation method, the 9a in compound 9o alternative method and farnesyl thiosalicylic acid acyl chloride reaction make faint yellow oily matter N-(6-(3-(3-methoxyl group-4-acetoxyl group phenyl) acrylic acid amides base) hexyl) farnesyl thiosalicylic acid acid amides (III
10), yield 63.8%.
1H NMR(CDCl
3,300MHz):8.01(s,1H,Ar-H),7.59-7.68(m,2H,Ar-H),7.55(m,1H,NH),7.39(m,2H,Ar-H),7.02(m,2H,Ar-H),6.87-6.84(d,1H,J=9Hz,COCH=C
H),6.26-6.21(d,1H,J=15Hz,COC
H=CH),5.87(m,1H,NH),5.26(m,1H,SCH
2C
H),5.08(m,2H,2×CH
2C
H=CCH
3),3.90(s,3H,OCH
3),3.46-3.61(m,6H,SCH
2,2×NCH
2),2.88(s,3H,COCH
3),1.97-2.02(m,8H,2×CHC
H 2C
H 2CH),1.50-1.71(m,16H,4×CH=CC
H 3,2×NCH
2C
H 2),1.43(m,4H,CH
2CH
2);ESI-MS(m/z):675[M+H]
+。
Embodiment 35N-(2-(3,4,5-trimethoxybenzoic acid amide group) ethyl) farnesyl thiosalicylic acid acid amides (III
11) preparation
(1) N-(2-amino-ethyl)-3,4, the preparation of 5-trimethoxybenzoic acid acid amides (9f)
Preparation method with reference to embodiment 25 steps (1) compound 9a, by 3,4, acetylsalicylic acid acyl chlorides and 1 in 5-trimethoxybenzoic acid acyl chlorides alternative method, the 2-reacting ethylenediamine makes white solid N-(2-amino-ethyl)-3,4,5-trimethoxybenzoic acid acid amides (9f), yield 76.6%;
(2) N-(2-(3,4,5-trimethoxybenzoic acid amide group) ethyl) farnesyl thiosalicylic acid acid amides (III
11) preparation with reference to embodiment 25 steps (2) compound III
1the preparation method, the 9a in compound 9f alternative method and farnesyl thiosalicylic acid acyl chloride reaction make yellow oil N-(2-(3,4,5-trimethoxybenzoic acid amide group) ethyl) farnesyl thiosalicylic acid acid amides (III
11), yield 70.4%.
1H NMR(CDCl
3,300MHz):δ7.81(m,1H,Ar-H),7.46(m,1H,Ar-H),7.32(m,1H,Ar-H),7.23(m,1H,Ar-H),7.12(m,2H,Ar-H),5.29-5.20(t,1H,J=15Hz,SCH
2C
H),5.10(m,2H,2×CH
2C
H=CCH
3),3.83(m,9H,3×OC
H 3),3.71-3.45(m,6H,SC
H 2,2×NC
H 2),2.01-1.98(m,8H,2×CHC
H 2C
H 2CH),1.70-1.63(m,12H,4×CH=CC
H 3),;ESI-MS(m/z):595[M+H]
+。
Embodiment 35N-(3-(3,4,5-trimethoxybenzoic acid amide group) propyl group) farnesyl thiosalicylic acid acid amides (III
12) preparation
(1) N-(3-aminopropyl)-3,4, the preparation of 5-trimethoxybenzoic acid acid amides (9g)
Preparation method with reference to embodiment 25 steps (1) compound 9a, by 1,3-propylene diamine and 3,4,1,2-diaminoethane in 5-trimethoxybenzoic acid acyl chlorides alternative method and acetylsalicylic acid acyl chloride reaction make white solid N-(3-aminopropyl)-3,4,5-trimethoxybenzoic acid acid amides (9g), yield 79.2%;
(2) N-(3-(3,4,5-trimethoxybenzoic acid amide group) propyl group) farnesyl thiosalicylic acid acid amides (III
12) preparation
With reference to embodiment 25 steps (2) compound III
1the preparation method, the 9a in compound 9g alternative method and farnesyl thiosalicylic acid acyl chloride reaction make transparent oily matter N-(3-(3,4,5-trimethoxybenzoic acid amide group) propyl group) farnesyl thiosalicylic acid acid amides (III
12), yield 67.2%.
1H NMR(CDCl
3,300MHz):δ7.81(m,1H,Ar-H),7.57(m,1H,Ar-H),7.31(m,1H,Ar-H),7,22(m,1H,Ar-H),7.15(m,2H,Ar-H),5.30-5.20(t,1H,J=15Hz,SCH
2C
H),5.07(m,2H,2×CH
2C
H=CCH
3),3.88(m,9H,3×OC
H 3),3.74-3.40(m,6H,SC
H 2,2×NC
H 2),2.01-1.98(m,8H,2×CHC
H 2C
H 2CH),1.70-1.57(m,14H,4×CH=CC
H 3,CH
2C
H 2CH
2),;ESI-MS(m/z):609[M+H]
+。
Embodiment 37N-(4-(3,4,5-trimethoxybenzoic acid amide group) butyl) farnesyl thiosalicylic acid acid amides (III
13) preparation
(1) N-(4-aminobutyl)-3,4, the preparation of 5-trimethoxybenzoic acid acid amides (9h)
With reference to the preparation method of embodiment 25 steps (1) compound 9a, by 1,2-diaminoethane and acetylsalicylic acid acyl chloride reaction in Putriscine and 3,4,5-trimethoxybenzoic acid acyl chlorides alternative method, make white solid, yield 82.5%.
(2) N-(4-(3,4,5-trimethoxybenzoic acid amide group) butyl) farnesyl thiosalicylic acid acid amides (III
13) preparation with reference to embodiment 25 steps (2) compound III
1the preparation method, the 9a in compound 9h alternative method and farnesyl thiosalicylic acid acyl chloride reaction make transparent oily matter N-(4-(3,4,5-trimethoxybenzoic acid amide group) butyl) farnesyl thiosalicylic acid acid amides (III
13), yield 65.9%.
1H NMR(CDCl
3,300MHz):δ7.73(m,1H,Ar-H),7.52(m,1H,Ar-H),7.38(m,1H,Ar-H),7.21(m,1H,Ar-H),7.10(m,2H,Ar-H),5.23(t,1H,J=15Hz,SCH
2C
H),5.02(m,2H,2×CH
2C
H=CCH
3),3.81(m,9H,3×OC
H 3),3.72-3.41(m,6H,SC
H 2,2×NC
H 2),2.00-1.96(m,8H,2×CHC
H 2C
H 2CH),1.72-1.54(m,16H,4×CH=CC
H 3,CH2CH
2C
H 2CH
2),;ESI-MS(m/z):623[M+H]
+。
Embodiment 38N-(5-(3,4,5-trimethoxybenzoic acid amide group) amyl group) farnesyl thiosalicylic acid acid amides (III
14) preparation
(1) N-(the amino amyl group of 5-)-3,4, the preparation of 5-trimethoxybenzoic acid acid amides (9i)
Preparation method with reference to embodiment 25 steps (1) compound 9a, by 1,5-pentamethylene diamine and 3,4,1,2-diaminoethane in 5-trimethoxybenzoic acid acyl chlorides alternative method and acetylsalicylic acid acyl chloride reaction make white solid N-(the amino amyl group of 5-)-3,4,5-trimethoxybenzoic acid acid amides (9i), yield 80.3%;
(2) N-(5-(3,4,5-trimethoxybenzoic acid amide group) amyl group) farnesyl thiosalicylic acid acid amides (III
14) preparation with reference to embodiment 25 steps (2) compound III
1the preparation method, the 9a in compound 9i alternative method and farnesyl thiosalicylic acid acyl chloride reaction make transparent oily matter N-(5-(3,4,5-trimethoxybenzoic acid amide group) amyl group) farnesyl thiosalicylic acid acid amides (III
14), yield 67.6%.
1H NMR(CDCl
3,300MHz):δ7.74(m,1H,Ar-H),7.55(m,1H,Ar-H),7.37(m,1H,Ar-H),7.20(m,1H,Ar-H),7.12(m,2H,Ar-H),5.32(t,1H,J=15Hz,SCH
2C
H),5.07(m,2H,2×CH
2C
H=CCH
3),3.70(m,9H,3×OC
H 3),3.72-3.41(m,6H,SC
H 2,2×NC
H 2),2.00-1.96(m,8H,2×CHC
H 2C
H 2CH),1.73-1.52(m,16H,4×CH=CC
H 3,2×CH
2),1.32(m,2H,CH
2);ESI-MS(m/z):637[M+H]
+。
Embodiment 39N-(6-(3,4,5-trimethoxybenzoic acid amide group) hexyl) farnesyl thiosalicylic acid acid amides (III
15) preparation
(1) N-(the amino hexyl of 6-)-3,4, the preparation of 5-trimethoxybenzoic acid acid amides (9j)
With reference to the preparation method of embodiment 25 steps (1) compound 9a, by 1,2-diaminoethane and acetylsalicylic acid acyl chloride reaction in 1,6-hexanediamine and 3,4,5-trimethoxybenzoic acid acyl chlorides alternative method, make white solid, yield 84.6%;
(2) N-(6-(3,4,5-trimethoxybenzoic acid amide group) hexyl) farnesyl thiosalicylic acid acid amides (III
15) preparation
With reference to embodiment 25 steps (2) compound III
1the preparation method, the 9a in compound 9j alternative method and farnesyl thiosalicylic acid acyl chloride reaction make transparent oily matter N-(6-(3,4,5-trimethoxybenzoic acid amide group) hexyl) farnesyl thiosalicylic acid acid amides (III
15), yield 71.6%.
1H NMR(CDCl
3,300MHz):δ7.62(m,1H,Ar-H),7.36(m,1H,Ar-H),7.31(m,1H,Ar-H),7.28(m,1H,Ar-H),7.11(m,2H,Ar-H),5.28-5.23(t,1H,J=15Hz,SCH
2C
H),5.11-5.06(m,2H,2×CH
2C
H=CCH
3),3.87(m,9H,3×OC
H 3),3.55-3.45(m,6H,SC
H 2,2×NC
H 2),2.02-1.99(m,8H,2×CHC
H 2C
H 2CH),1.70-1.63(m,12H,4×CH=CCH
3),1.54(m,8H,C
H 2C
H 2C
H 2C
H 2);ESI-MS(m/z):651[M+H]
+。
Embodiment 40N-(2-(2 hydroxybenzoic acid amide group) ethyl) farnesyl thiosalicylic acid acid amides (III
16) preparation
By 0.5g (0.89mmol) compound III
1be dissolved in 10mL methyl alcohol, the aqueous solution that adds wherein the NaOH of 1mL 1mol/L, 60 ℃ of lower stirring reaction 2h, steam except methyl alcohol 1N salt acid for adjusting pH to 6, ethyl acetate (50mL * 3) extraction, merge organic phase, drying, filter, concentrated 0.38g oily matter N-(2-(2 hydroxybenzoic acid amide group) ethyl) the farnesyl thiosalicylic acid acid amides (III that obtains
16), yield 82.1%.
1H NMR(CDCl
3,300MHz):8.19(m,1H,Ar-H),7.62(m,2H,Ar-H),7.25(m,3H,Ar-H),6.56(m,2H,Ar-H),5.26(m,1H,SCH
2C
H),5.08(m,2H,2×CH
2C
H=CCH
3),3.55(m,6H,SCH
2,2×NCH
2),2.01(m,8H,2×CHC
H 2C
H 2CH),1.70(m,12H,4×CH
3);ESI-MS(m/z):521[M+H]
+。
Embodiment 41N-(3-(2 hydroxybenzoic acid amide group) propyl group) farnesyl thiosalicylic acid acid amides (III
17) preparation
With reference to embodiment 40 compound III
16the preparation method, by the compound III
2compound III 1 in alternative method is hydrolyzed and obtains oily matter N-(3-(2 hydroxybenzoic acid amide group) propyl group) farnesyl thiosalicylic acid acid amides (III under the effect of the NaOH of 1mol/L
17), yield 80.7%.
1H NMR(CDCl
3,300MHz):8.00(s,1H,Ar-H),7.62(d,1H,J=6.0Hz,Ar-H),7.31(m,4H,Ar-H),7.20(m,2H,Ar-H),6.95(m,1H,NH),5.82(m,1H,NH),5.36(s,1H,OH)5.25(m,1H,SCH
2C
H),5.02(m,2H,2×CH
2C
H=CCH
3),3.51(d,2H,J=9.0Hz,SCH
2),3.42-3.30(m,2H,2×NCH
2),1.97-2.02(m,10H,2×CHC
H 2C
H 2CH,CH
2C
H 2CH
2),1.50-1.75(m,12H,4×CH
3);ESI-MS(m/z):535[M+H]
+。
Embodiment 42N-(4-(2 hydroxybenzoic acid amide group) butyl) farnesyl thiosalicylic acid acid amides (III
18) preparation
With reference to the preparation method of embodiment 40 compound III 16, by the compound III
3compound III in alternative method
1under the NaOH of 1mol/L effect, hydrolysis obtains oily matter N-(4-(2 hydroxybenzoic acid amide group) butyl) farnesyl thiosalicylic acid acid amides (III
18), yield 78.3%.
1H NMR(CDCl
3,300MHz):δ7.68(m,2H,Ar-H),7.40(m,2H,Ar-H),7.34(m,2H,Ar-H),6.91(m,1H,Ar-H),5.28-5.24(t,1H,J=15Hz,SCH
2C
H),5.11-5.06(t,2H,J=15Hz,2×CH
2C
H=CCH
3),3.49(m,6H,SC
H 2,2×CONC
H 2),2.02-1.98(m,8H,2×CHCH
2CH
2CH),1.71-1.68(m,12H,4×CH=CCH
3),1.60-154(m,4H,2×NCH
2C
H 2);ESI-MS (m/z):549[M+H]
+。
Embodiment 43N-(5-(2 hydroxybenzoic acid amide group) amyl group) farnesyl thiosalicylic acid acid amides (III
19) preparation
With reference to embodiment 40 compound III
16the preparation method, by the compound III
4compound III in alternative method
1under the NaOH of 1mol/L effect, hydrolysis obtains oily matter N-(5-(2 hydroxybenzoic acid amide group) amyl group) farnesyl thiosalicylic acid acid amides (III
19), yield 82.3%.
1H NMR(CDCl
3,300MHz):8.00(s,1H,Ar-H),7.61(d,1H,J=6.0Hz,Ar-H),7.43(m,2H,Ar-H),7.30(m,2H,Ar-H),7.20(m,2H,Ar-H),6.81(m,1H,NH),5.69(m,1H,NH),5.38(m,1H,OH),5.23(m,1H,SCH
2C
H),5.04(m,2H,2×CH
2C
H=CCH
3),3.53(d,2H,J=9.0Hz,SCH
2),3.40(m,2H,2×NCH
2),1.87-2.02(m,8H,2×CHC
H 2C
H 2CH),1.52-1.74(m,16H,4×CH=CC
H 3,2×CH
2),1.39(m,2H,CH
2);ESI-MS(m/z):563[M+H]
+。
Embodiment 44N-(6-(2 hydroxybenzoic acid amide group) hexyl) farnesyl thiosalicylic acid acid amides (III
20) preparation
With reference to embodiment 40 compound III
16the preparation method, by the compound III
5compound III in alternative method
1under the NaOH of 1mol/L effect, hydrolysis obtains oily matter N-(6-(2 hydroxybenzoic acid amide group) hexyl) farnesyl thiosalicylic acid acid amides (III
20), yield 77.2%.
1H NMR(CDCl
3,300MHz):8.05(s,1H,Ar-H),7.65(d,1H,J=6.0Hz,Ar-H),7.36(m,2H,Ar-H),7.35(m,2H,Ar-H),7.26(m,2H,Ar-H),6.83(m,1H,NH),5.72(m,1H,NH),5.32(m,1H,OH),5.21(m,1H,SCH
2C
H),5.11(m,2H,2×CH
2C
H=CCH
3),3.56(d,2H,J=9.0 Hz,SCH
2),3.48(m,2H,NCH
2),3.25(m,2H,NCH
2),1.97-2.01(m,8H,2×CHC
H 2C
H 2CH),1.52-1.76(m,16H,4×CH=CC
H 3,2×NCH
2C
H 2),1.36(m,4H,CH
2CH
2);ESI-MS (m/z):577[M+H]
+。
Embodiment 45N-(2-(3-(3-methoxyl group-4-hydroxy phenyl) acrylic acid amides base) ethyl) farnesyl thiosalicylic acid acid amides (III
21) preparation
With reference to embodiment 40 compound III
16the preparation method, by the compound III
11compound III in alternative method
1under the effect of the NaOH of 1mol/L, hydrolysis obtains oily matter N-(2-(3-(3-methoxyl group-4-hydroxy phenyl) acrylic acid amides base) ethyl) farnesyl thiosalicylic acid acid amides (III
21), yield 83.6%.
1H NMR(CDCl
3,300MHz):δ7.64(m,2H,Ar-H),7.40(m,2H,Ar-H),7.06(m,2H,Ar-H),6.91(m,1H,Ar-H),6.91-6.88(d,1H,J=9.0 Hz,COCH=C
H),6.39-6.34(d,1H,J=15.0Hz,COC
H=CH),5.27(m,1H,SCH
2C
H),5.08(m,2H,2×CH
2CH=CCH
3),3.93(m,3H,OCH
3),3.58-3.55(m,6H,SC
H 2,NC
H 2C
H 2N),2.01(m,8H,2×CHC
H 2C
H 2CH),1.68(m,12H,4×CH=CC
H 3);ESI-MS (m/z):577[M+H]
+。
Embodiment 46N-(3-(3-(3-methoxyl group-4-hydroxy phenyl) acrylic acid amides base) propyl group) farnesyl thiosalicylic acid acid amides (III
22) preparation
With reference to embodiment 40 compound III
16the preparation method, by the compound III
12compound III in alternative method
1under the effect of 1mol/LNaOH, hydrolysis obtains oily matter N-(3-(3-(3-methoxyl group-4-hydroxy phenyl) acrylic acid amides base) propyl group) farnesyl thiosalicylic acid acid amides (III
22), yield 86.1%.
1H NMR(CDCl
3,300MHz):δ7.63(m,1H,Ar-H),7.52(m,1H,Ar-H),7.38(m,2H,Ar-H),7.06(m,3H,Ar-H),6.91-6.88(d,1H,J=9.0Hz,COCH=C
H),6.38-6.33(d,1H,J=15.0Hz,COC
H=CH),5.27(m,1H,SCH
2CH),5.07(m,2H,2×CH
2CH=CCH
3),3.39(s,3H,OC
H 3),3.57-3.52(m,6H,SCH
2,2×NC
H 2),2.02-1.97(m,8H,2×CHC
H 2C
H 2CH),1.55-1.67(m,14H,4×CH=CC
H 3,NCH
2C
H 2);ESI-MS(m/z):591[M+H]
+。
Embodiment 47N-(4-(3-(3-methoxyl group-4-hydroxy phenyl) acrylic acid amides base) butyl) farnesyl thiosalicylic acid acid amides (III
23) preparation
With reference to embodiment 40 compound III
16the preparation method, by the compound III
13compound III in alternative method
1under the effect of 1mol/LNaOH, hydrolysis obtains oily matter N-(4-(3-(3-methoxyl group-4-hydroxy phenyl) acrylic acid amides base) butyl) farnesyl thiosalicylic acid acid amides (III
23), yield 73.8%.
1H NMR(CDCl
3,300MHz):8.00(s,1H,Ar-H),7.46-7.65(m,2H,Ar-H,NH),7.32(m,2H,Ar-H),7.12(m,2H,Ar-H),6.96-6.93(m,1H,J=9Hz,COCH=C
H),6.23-6.18(d,1H,J=15Hz,COC
H=CH),5.89(m,1H,NH),5.20(m,1H,SCH
2C
H),5.01(m,2H,2×CH
2C
H=CCH
3),3.82(s,3H,OCH
3),3.53-3.41(m,6H,SCH
2,2×NCH
2),1.90-2.01(m,8H,2×CHC
H 2C
H 2CH),1.50-1.76(m,16H,4×CH=CCH
3,CH
2C
H 2C
H 2CH
2);ESI-MS(m/z):605[M+H]
+。
Embodiment 48N-(5-(3-(3-methoxyl group-4-hydroxy phenyl) acrylic acid amides base) amyl group) farnesyl thiosalicylic acid acid amides (III
24) preparation
With reference to embodiment 40 compound III
16the preparation method, by the compound III
14compound III in alternative method
1under the effect of 1mol/LNaOH, hydrolysis obtains oily matter N-(5-(3-(3-methoxyl group-4-hydroxy phenyl) acrylic acid amides base) amyl group) farnesyl thiosalicylic acid acid amides (III
24), yield 82.3%.
1H NMR(CDCl
3,300MHz):8.01(s,1H,Ar-H),7.57-7.70(m,2H,Ar-H,NH),7.32(m,2H,Ar-H),7.02(m,2H,Ar-H),6.99-6.96(m,1H,J=9Hz,COCH=C
H),6.26-6.21(d,1H,J=15Hz,COC
H=CH),5.93(m,1H,NH),5.24(m,1H,SCH
2C
H),5.18(m,2H,2×CH
2C
H=CCH
3),3.73(s,3H,OCH
3),3.52-3.40(m,6H,SCH
2,2×NCH
2),1.97-2.00(m,8H,2×CHC
H 2C
H 2CH),1.52-1.70(m,16H,4×CH=CC
H 3,2×CH
2),1.40(m,2H,CH
2);ESI-MS (m/z):619[M+H]
+。
Embodiment 49N-(6-(3-(3-methoxyl group-4-hydroxy phenyl) acrylic acid amides base) hexyl) farnesyl thiosalicylic acid acid amides (III
25) preparation
With reference to embodiment 40 compound III
16the preparation method, by the compound III
15compound III in alternative method
1under the effect of 1mol/LNaOH, hydrolysis obtains oily matter N-(6-(3-(3-methoxyl group-4-hydroxy phenyl) acrylic acid amides base) hexyl) farnesyl thiosalicylic acid acid amides (III
25), yield 83.6%.
1H NMR(CDCl
3,300MHz):8.01(s,1H,Ar-H),7.59-7.68(m,2H,Ar-H),7.87(m,1H,NH),7.32(m,2H,Ar-H),7.03(m,2H,Ar-H),6.87-6.84(d,1H,J=9Hz,COCH=C
H),6.26-6.21(d,1H,J=15Hz,COC
H=CH),5.87(m,1H,NH),5.26(m,1H,SCH
2C
H),5.08(m,2H,2×CH
2C
H=CCH
3),3.92(s,3H,OCH
3),3.46-3.60(m,6H,SCH
2,2×NCH
2),1.99-2.01(m,8H,2×CHC
H 2C
H 2CH),1.54-1.73(m,16H,4×CH=CC
H 3,2×NCH
2C
H 2),1.43(m,4H,CH
2CH
2);ESI-MS(m/z):633[M+H]
+。
Embodiment 50N-(2-(Gallic Acid amide group) ethyl) farnesyl thiosalicylic acid acid amides (III
26) preparation
By the compound III
110.65g (1.1mmol) be dissolved in the 15mL methylene dichloride, drip the boron tribromide dichloromethane solution that 10mL concentration is 1M, during continuation reaction 3h falls back, with dry concentrated after dichloromethane extraction, column chromatography for separation, obtain faint yellow waxy solid N-(2-(Gallic Acid amide group) ethyl) farnesyl thiosalicylic acid acid amides (III
26), yield 51.2%.
1H NMR(CDCl
3,300MHz):δ7.80(m,1H,Ar-H),7.46(m,1H,Ar-H),7.32(m,1H,Ar-H),7.23(m,1H,Ar-H),7.12(m,2H,Ar-H),5.38(m,3H,3×OH),5.29-5.20(t,1H,J=15Hz,SCH
2C
H),5.10(m,2H,2×CH
2C
H=CCH
3),3.71-3.45(m,6H,SC
H 2,2×NC
H 2),2.01-1.98(m,8H,2×CHC
H 2C
H 2CH),1.70-1.63(m,12H,4×CH=CC
H 3),;ESI-MS(m/z):553[M+H]
+。
Embodiment 51N-(3-(Gallic Acid amide group) propyl group) farnesyl thiosalicylic acid acid amides (III
27) preparation
With reference to embodiment 50 compound III
26the preparation method, by the compound III
12compound III in replacement method
11dichloromethane solution reaction with the 1M boron tribromide, make faint yellow waxy solid N-(3-(Gallic Acid amide group) propyl group) farnesyl thiosalicylic acid acid amides (III
27), yield 47.4%.
1H NMR(CDCl
3,300MHz):δ7.80(m,1H,Ar-H),7.61(m,1H,Ar-H),7.33(m,1H,Ar-H),7.22(m,1H,Ar-H),7.19(m,2H,Ar-H),5.35(m,3H,3×OH),5.31-5.20(t,1H,J=15Hz,SCH
2C
H),5.02(m,2H,2×CH
2C
H=CCH
3),3.74-3.40(m,6H,SC
H 2,2×NC
H 2),2.00-1.91(m,8H,2×CHC
H 2C
H 2CH),1.77-1.56(m,14H,4×CH=CC
H 3,CH
2C
H 2CH
2),;ESI-MS(m/z):567[M+H]
+。
Embodiment 52N-(4-(Gallic Acid amide group) butyl) farnesyl thiosalicylic acid acid amides (III
28) preparation
With reference to embodiment 50 compound III
26the preparation method, by the compound III
13compound III in replacement method
11dichloromethane solution reaction with the 1M boron tribromide, make faint yellow waxy solid N-(4-(Gallic Acid amide group) butyl) farnesyl thiosalicylic acid acid amides (III
28), yield 45.8%.
1H NMR(CDCl
3,300MHz):δ7.74(m,1H,Ar-H),7.51(m,1H,Ar-H),7.38(m,1H,Ar-H),7.21(m,1H,Ar-H),7.10(m,2H,Ar-H),5.35(m,3H,3×OH),5.20(t,1H,J=15Hz,SCH
2C
H),5.00(m,2H,2×CH
2C
H=CCH
3),3.73-3.41(m,6H,SC
H 2,2×NC
H 2),2.02-1.98(m,8H,2×CHC
H 2C
H 2CH),1.74-1.52(m,16H,4×CH=CC
H 3,2×NCH
2C
H 2),;ESI-MS(m/z):581[M+H]
+。
Embodiment 53N-(5-(Gallic Acid amide group) amyl group) farnesyl thiosalicylic acid acid amides (III
29) preparation
With reference to embodiment 50 compound III
26the preparation method, by the compound III
14compound III in replacement method
11dichloromethane solution reaction with the 1M boron tribromide, make faint yellow waxy solid N-(5-(Gallic Acid amide group) amyl group) farnesyl thiosalicylic acid acid amides (III
29), yield 43.6%.
1H NMR(CDCl
3,300MHz):δ7.87(m,1H,Ar-H),7.55(m,1H,Ar-H),7.37(m,1H,Ar-H),7.21(m,1H,Ar-H),7.12(m,2H,Ar-H),5.39(m,3H,3×OH),5.21(t,1H,J=15Hz,SCH
2C
H),5.07(m,2H,2×CH
2C
H=CCH
3),3.72-3.42(m,6H,SC
H 2,2×NC
H 2),2.03-1.96(m,8H,2×CHC
H 2C
H 2CH),1.73-1.50(m,16H,4×CH=CC
H 3,2×NCH
2C
H 2),1.32(m,2H,CH
2);ESI-MS(m/z):595[M+H]
+。
Embodiment 54N-(6-(Gallic Acid amide group) hexyl) farnesyl thiosalicylic acid acid amides (III
30) preparation
With reference to embodiment 50 compound III
26the preparation method, by the compound III
15compound III in replacement method
11dichloromethane solution reaction with the 1M boron tribromide, make faint yellow waxy solid N-(6-(Gallic Acid amide group) hexyl) farnesyl thiosalicylic acid acid amides (III
30), yield 44.1%.
1H NMR(CDCl
3,300MHz):δ7.68(m,1H,Ar-H),7.38(m,1H,Ar-H),7.31(m,1H,Ar-H),7.22(m,1H,Ar-H),7.07(m,2H,Ar-H),5.35(m,3H,3×OH),5.28-5.23(t,1H,J=15Hz,SCH
2C
H),5.11-5.06(m,2H,2×CH
2C
H=CCH
3),3.55-3.45(m,6H,SC
H 2,2×NC
H 2),2.02-1.99(m,8H,2×CHC
H 2C
H 2CH),1.56-1.67(m,16H,4×CH
3,2×NCH
2C
H 2),1.52-1.44(m,4H,CH
2CH
2);ESI-MS(m/z):609[M+H]
+。
Embodiment 55N-(3-farnesyl thiosalicylic acid amidopropyl) farnesyl thiosalicylic acid acid amides (III
31) preparation
1,3-propylene diamine and triethylamine are dissolved in to anhydrous CH
2cl
2, the anhydrous CH of dripping method Thessaloniki thiosalicylic acid acyl chlorides under ice bath
2cl
2solution, drip complete stirring at room 1h, and steaming desolventizes, triethylamine, and column chromatography obtains off-white color oily matter N-(3-farnesyl thiosalicylic acid amidopropyl) farnesyl thiosalicylic acid acid amides (III
31), yield 63.2%.
1H NMR(CDCl
3,300MHz):δ7.72(m,2H,Ar-H),7.40(m,4H,Ar-H),6.81(m,2H,Ar-H),5.29(m,2H,2×SCH
2C
H),5.09(m,4H,4×CH
2C
H=CCH
3),3.49-3.53(m,8H,2×SC
H 2,2×CONHC
H 2),2.02-1.90(m,18H,4×CHC
H 2C
H 2CH,CH
2C
H 2CH
2),1.54-1.73(m,24H,8×CH=CC
H 3),;ESI-MS (m/z):755[M+H]
+。
Embodiment 56N-(4-farnesyl thiosalicylic acid amide group butyl) farnesyl thiosalicylic acid acid amides (III
32) preparation
With reference to embodiment 55 compound III
31the preparation method, in the Putriscine replacement method 1,3-propylene diamine and farnesyl thiosalicylic acid acyl chloride reaction make colorless oil N-(4-farnesyl thiosalicylic acid amide group butyl) farnesyl thiosalicylic acid acid amides (III
32), yield 67.8%.
1H NMR(CDCl
3,300MHz):δ7.72(m,2H,Ar-H),7.40(m,4H,Ar-H),6.81(m,2H,Ar-H),5.29(m,2H,2×SCH
2C
H),5.09(m,4H,4×CH
2C
H=CCH
3),3.49-3.53(m,8H,2×SC
H 2,2×CONHC
H 2),2.02(m,16H,4×CHC
H 2C
H 2CH),1.50-1.71(m,24H,8×CH=CC
H 3),1.23(m,4H,2×NHCH
2C
H 2);ESI-MS(m/z):769[M+H]
+。
Embodiment 57N-(5-farnesyl thiosalicylic acid amide group amyl group) farnesyl thiosalicylic acid acid amides (III
33) preparation
With reference to embodiment 55 compound III
31the preparation method, by 1 in 1,5-pentamethylene diamine replacement method, 3-propylene diamine and farnesyl thiosalicylic acid acyl chloride reaction make colorless oil N-(5-farnesyl thiosalicylic acid amide group amyl group) farnesyl thiosalicylic acid acid amides (III
33), yield 54.2%.
1H NMR(CDCl
3,300MHz):δ7.65(m,2H,Ar-H),7.35(m,4H,Ar-H),6.88(m,2H,Ar-H),5.28(m,2H,2×SCH
2C
H),5.09(m,4H,4×CH
2C
H=CCH
3),3.48-3.53(m,8H,2×SC
H 2,2×CONHC
H 2),2.01(m,16H,4×CHC
H 2C
H 2CH),1.53-1.70(m,24H,8×CH=CC
H 3),1.26(m,4H,2×NHCH
2C
H 2),0.89(m,2H,NHCH
2CH
2C
H 2);ESI-MS(m/z):783[M+H]
+。
Blue colorimetry (MTT) antitumor activity in vitro of embodiment 58 tetramethyl-nitrogen azoles
The antiproliferative activity of the compounds of this invention to 6 kinds of human cancer cell strains that adopted routinely MTT to estimate.Mtt assay has been widely used in the responsive mensuration of large-scale screening anti-tumor medicine, cell toxicity test and tumour radiotherapy etc.Select FTA as positive control drug.
Human cancer cell strain: liver cancer cell Hep 3B, lung cell A549, pancreatic cancer cell PANC-1, breast cancer cell MDA-MB-231, brain cancer cell U251, colon cancer cell HCT116.
Experimental technique is as follows: get in one bottle, cell in good condition exponential phase of growth, add 0.25% tryptic digestion, attached cell is come off, make every milliliter containing 2 * 10
4~ 4 * 10
4the suspension of individual cell.Obtained cell suspension is inoculated on 96 orifice plates, and every hole 180 μ L, put constant temperature CO
2in incubator, cultivate 24 hours.Change liquid, add test-compound I
1-I
18, compound ii
1-II
5or compound III
1-III
33(compound dilutes with PBS after dissolving with DMSO, and test-compound concentration is respectively 1 * 10
-7, 1 * 10
-6, 5 * 10
-5mol/L), every hole 20 μ L, cultivate 48 hours.MTT is added in 96 orifice plates, every hole 20 μ L, in incubator, reaction is 4 hours.Suck supernatant liquor, add DMSO, every hole 150 μ L, on dull and stereotyped shaking table, jolting is 5 minutes.Be the optical density that the 570nm place measures every hole with enzyme-linked immunosorbent assay instrument at wavelength, calculate cell inhibitory rate.Experimental result is as shown in table 4.
Cell inhibitory rate=(negative control group OD Zhi – tested material group OD value)/negative control group OD value * 100%.
The inhibiting rate % (25 μ mol/L) of table 4 the compounds of this invention to Partial tumors cell proliferation
Compounds | Hep 3B | A549 | U251 | PANC-1 | MDA-MB-231 | HCT116 |
FTA | 23.50 | 38.35 | 31.12 | 43.72 | 26.14 | 27.36 |
I 1 | 71.54 | 77.94 | 95.63 | 93.75 | 77.47 | 80.35 |
I 2 | 88.73 | 86.36 | 96.24 | 98.21 | 85.23 | 89.18 |
I 3 | 86.26 | 88.17 | 98.43 | 99.47 | 87.21 | 85.35 |
I 4 | 88.31 | 80.78 | 97.39 | 95.75 | 83.27 | 88.92 |
I 5 | 81.91 | 82.22 | 96.06 | 92.96 | 81.58 | 84.82 |
I 6 | 87.63 | 90.97 | 98.15 | 94.70 | 82.40 | 81.76 |
I 7 | 87.59 | 92.11 | 98.91 | 99.59 | 88.69 | 89.35 |
I 8 | 88.18 | 94.24 | 95.12 | 96.08 | 86.87 | 91.54 |
I 9 | 92.06 | 90.25 | 97.94 | 96.72 | 92.55 | 91.73 |
I 10 | 91.22 | 86.75 | 93.27 | 97.18 | 92.82 | 93.68 |
I 11 | 94.77 | 88.83 | 92.31 | 98.92 | 88.44 | ND |
I 12 | 95.66 | 92.56 | 95.33 | 93.06 | 92.56 | 90.32 |
I 13 | 90.18 | 91.36 | 90.73 | 96.61 | 85.61 | 96.53 |
I 14 | 84.33 | 87.31 | 93.78 | 96.11 | 88.23 | ND |
I 15 | 86.81 | 85.77 | 94.80 | 93.95 | 84.62 | ND |
I 16 | 88.38 | 86.17 | 92.11 | 96.76 | 86.72 | ND |
Ⅱ 1 | 92.70 | 91.55 | 92.77 | 96.98 | 90.36 | 88.22 |
Ⅱ 2 | 87.99 | 83.16 | 88.77 | 95.02 | 91.46 | 90.56 |
Ⅱ 3 | 89.53 | 84.94 | 81.3 | NA | 89.78 | 87.55 |
Ⅱ 4 | 88.64 | 87.38 | 88.48 | 94.11 | 90.22 | ND |
Ⅱ 5 | 89.43 | 85.29 | 96.26 | 95.36 | 88.96 | ND |
Ⅲ 2 | 1.63 | 6.25 | 3.56 | 2.38 | 8.45 | 7.34 |
Ⅲ 3 | 31.06 | 35.45 | 44.83 | 53.81 | 32.71 | 37.86 |
Ⅲ 9 | 3.54 | 5.72 | 3.28 | 1.93 | 4.64 | 4.44 |
Ⅲ 12 | 59.11 | 68.79 | 68.87 | 73.33 | 62.56 | ND |
Ⅲ 16 | 90.23 | 88.33 | 94.47 | 98.81 | 93.57 | 92.98 |
Ⅲ 18 | 92.85 | 88.32 | 98.93 | 99.83 | 92.70 | 88.35 |
Ⅲ 21 | 88.54 | 89.55 | 97.17 | 91.42 | 87.09 | 93.54 |
Ⅲ 22 | 94.21 | 91.68 | 94.37 | 96.56 | 92.14 | 85.69 |
Ⅲ 23 | 93.36 | 93.87 | 95.82 | 97.02 | 93.24 | 83.87 |
Ⅲ 31 | 48.86 | 57.05 | 69.85 | 56.09 | 63.98 | ND |
ND: do not detect.
Embodiment 59 flow cytometers detect apoptosis rate
Select pancreas cancer cell strain PANC-1, and, in the logarithmic phase state, add Digestive system (0.125% trypsinase+0.01%EDTA) digestion, count 2 ~ 2.5 * 10
5individual/ml, make cell suspension, is inoculated in culture plate, puts constant temperature CO
2in incubator, cultivate 24 hours.Use the DMEM culture medium culturing of 2% serum instead, add the tested medical compounds I of different concns
1-I
18, compound ii
1-II
5or compound III
1-III
33, continue to cultivate 48 hours.Collecting cell, attached cell is with not collecting containing the trysinization of EDTA, and the centrifugal 5min of 1000r/min, with cold PBS washed cell secondary (the centrifugal 5min of 1000rpm), after counting, adds approximately 1 * 10
5individual cell is centrifugal in test tube, removes supernatant.Suspension cell is in the Binding Buffer of 500 μ L.After adding 5 μ L AnnexinV-FITC to mix, add 5 μ L Propidium Iodide, mix, lucifuge reaction 5~15min.In 1 hour, carry out observation and the detection of flow cytometer.Excitation wavelength Ex=488nm; Emission wavelength Em=530nm.Every group 3 pipe.Without the negative contrast of the cell of drug treating.Apoptotic cell is AnnexinV
+and AnnexinV
+pI
+, and PI
+cell be non-viable non-apoptotic cell, non-transfect cell is damaging cells not.The apoptotic cell calculated in 200 cells is test index.The apoptosis rate of actual apoptosis rate=medicine apoptosis rate/negative control group.
Experimental result is found Compound I
1-I
18, compound ii
1-II
5or compound III
1-III
33cytotoxicity is in various degree all arranged, wherein, Compound I
7have stronger cytotoxicity at 12.5 μ mol/L in to PANC-1, apoptosis rate can reach 63%, and the LO2 cell is not had to obvious restraining effect, this results suggest Compound I
7optionally the apoptosis of inducing tumor cell, less to normal cell injury, thereby realize the effect of specific killing tumour cell.
The impact of Diamines FTA derivative on carcinoma of the pancreas PANC-1 cell Bcl-2, Bax and Caspase3 protein expression preferably of embodiment 60Western blot detection of active
A. cell is processed: getting the cell in the PANC-1 of logarithmic phase, is 10 with after 0.25% tryptic digestion, adjusting cell density
6/ ml is inoculated in 6 well culture plates, and every hole 1.0ml adds the tested medicine I of different concns
1-I
18, compound ii
1-II
5or compound III
1-III
33, continue to cultivate 48 hours.
B. total protein extracts and determination of protein concentration: add cell protein lysate and proteinase inhibitor to extract total protein.Below all in ice bath, carry out.4 ℃ of centrifugal 12000g, 15min, sucking-off supernatant (cell pyrolysis liquid).
The c.BCA method is measured total protein concentration.
D.SDS-PAGE and Western blot analyze: use respectively Bcl-2, Bax and Caspase3 primary antibodie and two to resist.
E. carry out gray scale scanning, PDQuest7.2.0 software analysis result.Using β-actin as internal reference, and identical experiment repeats 3 times.
Experimental result is found, Compound I under 6.125 μ M and 12.5 μ M concentration
1-I
18, compound ii
1-II
5or compound III
1-III
33the mode that suppresses cell proliferation is all relevant to inducing apoptosis of tumour cell in varying degrees, wherein Compound I
7the mechanism of action of its inducing apoptosis of tumour cell is mainly that the Bax protein expression increases by impelling, Bcl-2 down-regulated expression and activate Caspase 3 vigor and activate apoptosis pathway, produces short apoptosis effect.
Claims (10)
1. a Diamines alltrans farnesyl thio-salicylic acid derivative and pharmacy acceptable salt thereof have the structure of following general formula I:
In general formula I: n=1~9;
R
1represent H, CH
3(CH
3) CH, CH
3(CH
3) CHCH
2perhaps X (CH
2)
m, m=0~9 wherein, X=H;
R
2represent H, CH
3(CH
3) CH, CH
3(CH
3) CHCH
2perhaps Y (CH
2)
p, wherein, p=0~9, Y=H;
2. compound as claimed in claim 1 or its pharmacy acceptable salt, it is characterized in that n in the structure of described general formula I,
be selected from following combination:
Perhaps n=5,
Perhaps n=2,
Perhaps n=2,
Perhaps n=2,
Perhaps n=2,
Perhaps n=3,
4. a Diamines alltrans farnesyl thio-salicylic acid derivative and pharmacy acceptable salt thereof have the structure of following general formula I I:
In general formula I I: m=0~9; X=CH, N; N=0~3; O=0~3;
R represents CH
3(CH
3) CH, CH
3(CH
3) CHCH
2, or Y (CH
2)
p, wherein, p=0~9, Y=H, Ph or PhCH
2.
5. compound as claimed in claim 4 or its pharmacy acceptable salt is characterized in that m, n, o, X and the R in the structure of described general formula I I is selected from following combination:
m=1,n=2, o =2,X=CH,R=PhCH
2;
Perhaps, m=0, n=2, o=2, X=CH, R=PhCH
2;
Perhaps, m=1, n=2, o=2, X=CH, R=CH
3cH
2;
Perhaps, m=1, n=2, o=2, X=N, R=PhCH
2;
Perhaps, m=1, n=2, o=2, X=N, R=CH
3cH
2.
6. a Diamines alltrans farnesyl thio-salicylic acid derivative and pharmacy acceptable salt thereof have the structure of following general formula I II:
In general formula III: n=1~9;
7. compound as claimed in claim 6 or its pharmacy acceptable salt is characterized in that n and the R in the structure of described general formula III is selected from following combination:
N=3,4 or 5, R=2-OAcPh;
Perhaps n=1-5, R=3,4,5-OMePh;
Perhaps n=1-5, R=2-OHPh;
Perhaps n=2-4, R=2-S-farnesyl-Ph.
8. the preparation method of one of claim 1-7 described Diamines alltrans farnesyl thio-salicylic acid derivative and pharmacy acceptable salt thereof,
(1), the compound of Formula I synthetic route is as follows:
Wherein, in general formula I: n=1~9;
R
1represent H, CH
3(CH
3) CH, CH
3(CH
3) CHCH
2perhaps X (CH
2)
m, m=0~9 wherein, X=H;
R
2represent H, CH
3(CH
3) CH, CH
3(CH
3) CHCH
2perhaps Y (CH
2)
p, wherein, p=0~9, Y=H;
Step comprises:
By alltrans farnesyl thiosalicylic acid, under the effect of chloride reagent, described chloride reagent is sulfur oxychloride or oxalyl chloride, prepares alltrans farnesyl thiosalicylic acid acyl chlorides, by alltrans farnesyl thiosalicylic acid acyl chlorides and NH
2(CH
2)
ncH
2nR
1r
2in the dichloromethane solution of triethylamine or salt of wormwood or sodium carbonate, reaction obtains compound of Formula I;
Perhaps, alltrans farnesyl thiosalicylic acid and NH
2(CH
2)
ncH
2nR
1r
2under condensing agent and DMAP effect, condensation makes compound of Formula I;
General formula I preparation method as described above, it is characterized in that described condensing agent is selected from 1,3-dicyclohexylcarbodiimide, 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride, N, N-DIC, Vinyl chloroformate or methyl esters, solvent is selected from methylene dichloride, chloroform, tetrahydrofuran (THF), ethyl acetate, methyl acetate, 1, one or more in 2-ethylene dichloride, benzene, toluene, dioxane or dimethyl formamide;
(2), general formula I I compou nd synthesis route is as follows:
Wherein, in general formula I I: m=0~9; X=CH, N; N=0~3; O=0~3; R represents CH
3(CH
3) CH, CH
3(CH
3) CHCH
2, or Y (CH
2)
p, wherein, p=0~9, Y=H, Ph or PhCH
2;
Step comprises:
1) compound 2 reacts and obtains compound 4 with R-Br under the effect of salt of wormwood;
2) compound 4 reacts with methylsulfonyl chloride and obtains compound 5;
3) compound 5 reacts with excessive ammonia and obtains compound 6;
4) compound 6 reacts and obtains general formula I I compound with alltrans farnesyl thiosalicylic acid under condensing agent and DMAP effect, perhaps compound 6 and alltrans farnesyl thiosalicylic acid acyl chlorides react and obtain general formula I I compound under the effect of acid binding agent triethylamine or salt of wormwood;
General formula I I preparation method as described above; it is characterized in that step 4) described condensing agent is selected from 1; 3-dicyclohexylcarbodiimide, 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride, N; N-DIC or Vinyl chloroformate or methyl esters; solvent is selected from methylene dichloride, chloroform, tetrahydrofuran (THF), ethyl acetate, methyl acetate, 1, one or more in 2-ethylene dichloride, benzene, toluene, dioxane or dimethyl formamide;
(3), the general formula III synthetic route is as follows:
In general formula III: n=1~9;
R represents Ph, 2-OHPh, 2-SHPh, 2-S-farnesyl-Ph, 2-OAcPh, 2-SAcPh, 3-OHPh, 4-OHPh, 3,4-OHPh, 3,5-OHPh, 3-OMePh, 4-OMePh, 3,4-OMePh, 3,5-OMePh, 3,4,5-OMePh or
r wherein
3=OCH
3, R
4=OH;
Step comprises:
1) by compound 7 and NH
2(CH
2)
ncH
2nH
2under the effect of condensing agent, reaction obtains compound 9, or by compound 7 and chloride reagent reaction, described chloride reagent is sulfur oxychloride or oxalyl chloride, obtains corresponding acyl chlorides directly and NH
2(CH
2)
ncH
2nH
2under the effect of acid binding agent triethylamine or salt of wormwood, reaction obtains compound 9;
2) compound 9 reacts and obtains compound of formula III under condensing agent and DMAP effect with alltrans farnesyl thiosalicylic acid, perhaps compound 9 and alltrans farnesyl thiosalicylic acid acyl chlorides react the preparation compound of formula III under the effect of acid binding agent triethylamine or salt of wormwood;
Compound of formula III preparation method as described above, it is characterized in that step 1) and 2) described condensing agent is selected from 1,3-dicyclohexylcarbodiimide, 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride, N, N-DIC, Vinyl chloroformate or methyl esters, solvent is selected from methylene dichloride, chloroform, tetrahydrofuran (THF), ethyl acetate, methyl acetate, 1, one or more in 2-ethylene dichloride, benzene, toluene, dioxane or dimethyl formamide.
9. a pharmaceutical composition, the pharmaceutical composition that contains the described general formula I of claim 1-7 any one, II or III compound or its medically acceptable salt and pharmaceutically acceptable auxiliary material.
10. described general formula I, II or III compound or its medically acceptable salt of claim 1-7 any one is preparing Hepatoma therapy, carcinoma of the pancreas, lung cancer, mammary cancer, the cancer of the brain, the application in colorectal carcinoma and cancer of the stomach tumour medicine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012102016946A CN102702052B (en) | 2012-06-18 | 2012-06-18 | Novel diamine-containing farnesyl thiosalicylic acid derivative and preparation method and medicinal application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012102016946A CN102702052B (en) | 2012-06-18 | 2012-06-18 | Novel diamine-containing farnesyl thiosalicylic acid derivative and preparation method and medicinal application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102702052A CN102702052A (en) | 2012-10-03 |
CN102702052B true CN102702052B (en) | 2013-12-11 |
Family
ID=46895167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012102016946A Expired - Fee Related CN102702052B (en) | 2012-06-18 | 2012-06-18 | Novel diamine-containing farnesyl thiosalicylic acid derivative and preparation method and medicinal application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102702052B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103450062B (en) * | 2013-01-25 | 2014-09-24 | 南通大学 | Double-target point medicine compound for treating tumors as well as preparation method and application thereof |
CN103113274B (en) * | 2013-01-25 | 2013-12-11 | 南通大学 | Ras and HDAC dual inhibitor as well as preparation method and application thereof |
CN103450301B (en) * | 2013-09-09 | 2015-09-09 | 南通大学 | Farnesyl thiosalicylic acid-nucleosides conjugate, its preparation method and medicinal use thereof |
CN103864720B (en) * | 2014-01-23 | 2016-01-20 | 南通大学 | Derived from phenyl acrylic acid farnesyl thio-salicylic acid derivative and preparation method and purposes |
CN104292140B (en) * | 2014-08-25 | 2016-06-29 | 南通大学 | Farnesyl thiosalicylic acid-like substance containing chalcone skeleton and preparation method and purposes |
CN104292139B (en) * | 2014-08-25 | 2016-04-13 | 南通大学 | The chalcone derivative that farnesyl thioether replaces and preparation method and purposes |
CN104829671B (en) * | 2015-03-18 | 2017-07-21 | 南通大学 | The gemcitabine of NO donator types/FTA/ furazans conjugate and preparation method and purposes |
CN106619660A (en) * | 2016-12-20 | 2017-05-10 | 南京医科大学 | Application of FTS (Trans Farnesyl Thiosalicylic Acid/Salirasib) |
EP3630928B1 (en) * | 2017-05-31 | 2022-03-16 | Total Marketing Services | Compound comprising polyamine, acidic and boron fonctionalities and its use as a lubricant additive |
CN111925362B (en) * | 2020-08-20 | 2023-06-23 | 陕西中医药大学 | Anticancer compound and synthesis method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101812059A (en) * | 2010-04-14 | 2010-08-25 | 中国药科大学 | Nitric oxide donor-type farnesyl thiosalicylic acid derivative, and preparation method and medical application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050119237A1 (en) * | 1999-06-18 | 2005-06-02 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Non-malignant disease treatment with Ras antagonists |
AU2004266721A1 (en) * | 2003-08-22 | 2005-03-03 | University Of Virginia Patent Foundation | Blockade of mTOR to prevent a hormonal adaptive response |
US8338481B2 (en) * | 2009-01-28 | 2012-12-25 | Ramot At Tel-Aviv University Ltd. | Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer |
-
2012
- 2012-06-18 CN CN2012102016946A patent/CN102702052B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101812059A (en) * | 2010-04-14 | 2010-08-25 | 中国药科大学 | Nitric oxide donor-type farnesyl thiosalicylic acid derivative, and preparation method and medical application thereof |
Non-Patent Citations (9)
Title |
---|
Liat Goldberg等.New Derivatives of Farnesylthiosalicylic Acid (Salirasib) for Cancer Treatment: Farnesylthiosalicylamide Inhibits Tumor Growth in Nude Mice Models.《Journal of Medicinal Chemistry》.2008,第52卷第197-205页. |
Medicinal Chemistry》.2010,第18卷第3448-3456页. * |
New Derivatives of Farnesylthiosalicylic Acid (Salirasib) for Cancer Treatment: Farnesylthiosalicylamide Inhibits Tumor Growth in Nude Mice Models;Liat Goldberg等;《Journal of Medicinal Chemistry》;20081215;第52卷;第197-205页 * |
Novel Nitric Oxide-Releasing Derivatives of Farnesylthiosalicylic Acid: Synthesis and Evaluation of Antihepatocellular Carcinoma Activity;Yong Ling等;《Journal of Medicinal Chemistry》;20110419;第54卷;第3251-3259页 * |
NO供体型法尼基硫代水杨酸衍生物的合成及其抗肺癌活性;凌勇等;《中国药物化学杂志》;20101031;第20卷(第5期);第331-335,357页 * |
Yong Ling等.Novel Nitric Oxide-Releasing Derivatives of Farnesylthiosalicylic Acid: Synthesis and Evaluation of Antihepatocellular Carcinoma Activity.《Journal of Medicinal Chemistry》.2011,第54卷第3251-3259页. |
Yong Ling等.Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents.《Bioorganic & Medicinal Chemistry》.2010,第18卷第3448-3456页. |
Yong Ling等.Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents.《Bioorganic & * |
凌勇等.NO供体型法尼基硫代水杨酸衍生物的合成及其抗肺癌活性.《中国药物化学杂志》.2010,第20卷(第5期),第331-335,357页. |
Also Published As
Publication number | Publication date |
---|---|
CN102702052A (en) | 2012-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102702052B (en) | Novel diamine-containing farnesyl thiosalicylic acid derivative and preparation method and medicinal application thereof | |
CA2924206C (en) | Pyrimidine fgfr4 inhibitors | |
Mohan et al. | Indirubin, a bis-indole alkaloid binds to tubulin and exhibits antimitotic activity against HeLa cells in synergism with vinblastine | |
Ling et al. | Development of novel amino-quinoline-5, 8-dione derivatives as NAD (P) H: quinone oxidoreductase 1 (NQO1) inhibitors with potent antiproliferative activities | |
Fournier-Dit-Chabert et al. | Synthesis and biological evaluation of colchicine C-ring analogues tethered with aliphatic linkers suitable for prodrug derivatisation | |
Yang et al. | Biotin-Targeted Au (I) radiosensitizer for cancer synergistic therapy by intervening with redox homeostasis and inducing ferroptosis | |
Guo et al. | Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors | |
Liu et al. | Synthesis and discovery novel anti-cancer stem cells compounds derived from the natural triterpenoic acids | |
Routholla et al. | Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model | |
CN101967142B (en) | Thiazoleamide compound and medical application thereof in treating malignant tumor | |
CN103113274B (en) | Ras and HDAC dual inhibitor as well as preparation method and application thereof | |
Pósa et al. | Cytotoxicity of cinchona alkaloid organocatalysts against MES-SA and MES-SA/Dx5 multidrug-resistant uterine sarcoma cell lines | |
Guo et al. | Design, synthesis, and biological evaluation of ligustrazine-betulin amino-acid/dipeptide derivatives as anti-tumor agents | |
Obaid | New benzimidazole derivatives: Design, synthesis, docking, and biological evaluation | |
CN106565685A (en) | Tubulin inhibitor | |
CN113444075B (en) | Indoline derivative, preparation method thereof, pharmaceutical composition and application thereof | |
Chen et al. | Design, synthesis, and antitumor evaluation of morpholine substituted bisnaphthalimides as DNA targeting agents | |
Qin et al. | Discovery of 5-((4-(pyridin-3-yl) pyrimidin-2-yl) amino)-1H-indole-2-carboxamide derivatives as novel anti-cancer agents targeting Nur77 | |
Soliman et al. | Novel quinoline derivatives as antitumor agents against HepG2 cells: Synthesis, characterization, in silico, in vitro and docking studies | |
Zhou et al. | Discovery of novel 4 (1H)-quinolone derivatives as potential antiproliferative and apoptosis inducing agents | |
Zeng et al. | Design, synthesis and biological evaluation of novel HSP70 inhibitors: N, N′-disubstituted thiourea derivatives | |
CN104829671B (en) | The gemcitabine of NO donator types/FTA/ furazans conjugate and preparation method and purposes | |
Wang et al. | Design, synthesis and biological evaluation of some novel thiazole-2-carboxamide derivatives as antitumor agents | |
Wang et al. | Design, synthesis, and biological evaluation of novel protopanoxadiol derivatives based PROTACs technology for the treatment of lung cancer | |
CN103864720B (en) | Derived from phenyl acrylic acid farnesyl thio-salicylic acid derivative and preparation method and purposes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171103 Address after: Jishan Industrial Park 353300 Sanming Jiangle County public rental building A 4 Patentee after: FUJIAN JINHUA TECHNOLOGY Co.,Ltd. Address before: 226019 Jiangsu Province, Nantong City Chongchuan District sik Road No. 9 Patentee before: Nantong University |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131211 |